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Design, synthesis, and evaluation of aryl hydantoins and ureas as 
antischistosomal agents 
Chunkai Wang, Ph.D. 
University of Nebraska Medical Center, 2016 
Advisor: Yuxiang Dong, Ph.D. 
Schistosomiasis is a tropical parasitic disease caused by infections with flukes of the 
genus Schistosoma, affecting as many as 440 million individuals worldwide, with 779 million living 
at risk of infection. A new drug for schistosomiasis is urgently needed as praziquantel (PZQ) is 
currently the drug of last resort and the development of resistance cannot be ignored, particularly 
in view of its large-scale use in many endemic countries. Furthermore, PZQ is active against adult 
but not juvenile schistosomes; this may be an important factor in the frequently observed 
treatment ‘failures’ in areas endemic for schistosomiasis.  
The introduction of PZQ in 1982 likely led to decisions to abandon the development of a 
number of promising antischistosomal agents that were discovered in the same time period. One 
of these was AH01, the lead compound from a series of aryl hydantoins that were investigated in 
some detail at Hoffmann La-Roche. A number of characteristics of AH01 justify it as a compelling 
antischistosomal prototype. This work confirmed the high antischistosomal efficacy of AH01 and 
demonstrated that the aryl hydantoin is also effective against juvenile infections. Further, AH01 
had no measurable interaction with the androgen receptor in a ligand competition assay, but it did 
block DHT-induced cell proliferation in androgen-dependent cell line. For this aryl hydantoin, there 
appears to be no correlation between antischistosomal activity and androgen receptor interaction. 
Building on this foundation, a number of AH01 analogs were designed and synthesized to 
maximize structural diversity guided by incorporation of substructures and functional groups 
known to diminish ligand-AR interactions. This work identified several new derivatives of AH01 
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with low cytotoxicity and promising in vivo antischistosomal activities that set the stage for further 
optimization. 
This work also discovered that urea carboxylic acid UC00, the product formed by 
hydrolysis of the hydantoin substructure and AR33, a side-reaction product formed in the 
synthesis of the aryl hydantoins, have substantial in vivo antischistosomal efficacy. Base on this 
finding, novel N,N'-diaryl ureas were designed and synthesized as new analogues of AH01. The 
most promising compound identified in this work was N,N’-di(quinoxalin-2-yl)urea. This new lead 
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1.1 schistosomiasis overview 
Human schistosomiasis is the second most common tropical chronic disease 
caused by genus Schistosoma. There are five species of schistosomes, namely 
Schistosoma mansoni, S. japonicum, S. haematobium, S. intercalatum and S. mekongi. 
The former three have the widest geographical distributions and are of particular public 
health and economic impact.1 This disease is a huge burden on the healthcare system in 
developing countries in the tropics and subtropical regions. There are estimated 600 
million people at risk of infection.2 More than 230 million people have been affected by 
schistosome.3 More than 200,000 deaths annually are caused by a severe schistosomal 
infection in sub-Saharan Africa. 4 
The symptoms of this disease include a rash or itchy skin after becoming infected 
and fever, chills, cough, and muscle aches after 1-2 months of infection5. If the disease 
was left untreated, it could be lethal by renal failure or bladder cancer (S. haematobium) 
and acute hepatitis or liver fibrosis (S. mansoni)6. 
Long-term schistosomiasis contributes to poverty. Poverty reduces water use 
options and increases risk of schistosomal infection7. 
Many migrants and tourists come back from Africa after being infected with 
schistosomiasis through contact with contaminated fresh water leading to human 
schistosomiasis to be an emerging threat for Europe.8, 9 
1.2 Life cycle of schistosome 
Schistosome has a very complex life cycle in both snail intermediate hosts and 
the human hosts. The life cycle begins with the elimination of eggs with feces or urine 
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from the infected human host. If the eggs come in contact with water, they release 
miracidia, which search for and penetrate the suitable snail intermediate hosts. The 
miracidia develop into cercariae and leave the snails into the water. In human hosts, the 
cycle begins when cercariae penetrate the human skin. They migrate with the 
bloodstream to the liver and the mesenteric veins. After maturing into adult 
schistosomula, female worms deposit eggs which are moved to the intestine, bladder or 
ureters. The cycle starts again when these eggs are eliminated with feces or urine.1, 3, 10-
12 
1.3 Global distribution 
Schistosoma japonicum (Asia13, 14), S mansoni (Middle East15, Africa16-19 and 
South America20) and S haematobium (Africa16, 21 and Middle East15) are of regional and 
global importance. Schistosomiasis used to be endemic in Southern European (Portugal 
and Greece) until its eradication in the 1960s22. However, in August 2013, a German 
patient developed a urinary schistosomiasis, which became the first autochthonous case 
in Europe.23 In 2014, more than 258 million people required treatment for 
schistosomiasis. Compared to 2013, there was an increase of 14 million people treated 
for schistosomiasis in 2014, mainly in African Region.24 
1.4 Prevention 
It is difficult to eliminate intermediate hosts (snails) in schistosomiasis endemic 
areas, due to the high cost of chemical snail control (molluscicides) and high 
reproduction rate of snails25. The available methods to prevent and control 
schistosomiasis include clean water supplies26, better sanitation27, education25 and 
chemotherapy28. Preventive chemotherapy (mass treatment) at high-risk populations can 
result in significant reduction of schistosomal infection.29 
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1.5 Clinical features 
1.5.1. Cercarial dermatitis 
Cercarial dermatitis, known as ‘swimmer's itch', is a re-emerging disease in 
Europe.30 This disease is caused by penetration of the skin by larvae of schistosome. 
Parasites can migrate from the skin to the central nervous system or lungs. Extremely 
severe infections cause limb swelling, fever or diarrhea. The therapy of cercarial 
dermatitis includes topical application of abirritant powders or systemic administration of 
antihistaminics or corticosteroids.31, 32 
1.5.2. Katayama fever 
Acute schistosomiasis (Katayama fever) is ascribable to an immunologic 
response to the antigens present during the maturation process of the schistosomal 
worm. The patient may experience a cough, fever and urticarial rash with eosinophilia 
and pulmonary infiltrates. As the therapy for Katayama fever, a single oral dose of 
praziquantel is given after the acute stage.33, 34 
1.5.3. Genitourinary schistosomiasis 
Genitourinary schistosomiasis (bilharziasis) is caused by Schistosoma 
haematobium, which is the only species that infects the genitourinary system. The 
clinical symptoms of the early stages (within three months after infection) include dysuria, 
hematuria, ureteritis, pyelitis, and cystitis cystica. In the later stage of schistosomiasis, 
the deleterious function of the kidneys, ureters and bladder may be lethal due to renal 
failure or bladder cancer.35-37 
1.5.4. Intestinal schistosomiasis 
Immunologic adverse responses to schistosomal eggs which were trapped in the 
intestinal wall were associated with intestinal schistosomiasis.  If initial eosinophilic 
inflammation is not relieved, eventually granulomas would form around the eggs. The 
clinical symptoms range from abdominal pain, anemia, and diarrhea, to microulcerations, 
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pseudopolyps, and obstruction of the colon. In the late stage, hematemesis caused by 
bleeding from esophageal varices may be fatal.38, 39 
1.5.5. Neuroschistosomiasis 
Neuroschistosomiasis can occur at any stage of schistosomal infection.40 This 
disease refers to the schistosomal involvement of both the brain and the spinal cord.  
Schistosoma haematobium and S. mansoni usually cause myelopathy, while S. 
japonicum causes encephalic disease.41 Praziquantel and corticosteroids are the 
conventional treatment of neuroschistosomiasis. Surgery might be used for severe 
cases.42 The clinical symptoms include focal CNS impairment, seizures, increased 
intracranial pressure or transverse myelitis.40, 43 
1.5.6. Cardiopulmonary schistosomiasis 
Schistosomiasis was considered one of the main causes of pulmonary arterial 
hypertension (PAH). It is a severe disease with symptoms such as dyspnea, syncope, 
and peripheral edema.44 Most of the cardiopulmonary schistosomiasis are related to the 
portal hypertension, caused by the blockage of embolized schistosomal eggs.45 
 
1.6 Clinically used drug (Praziquantel) 
Chemotherapy is currently the only way to control schistosomiasis because no 
vaccine exists against schistosomiasis. The intermediate hosts (snails) are not easy to 
eliminate.46 Praziquantel (PZQ) is a synthetic tetracyclic tetrahydroisoquinoline 
derivative.47 The average cost of one treatment is $ 0.248 . However, the estimate cost of 
the treatment in KwaZulu-Natal, South Africa is $ 7.3 per child. Personnel, consumables, 









1.6.1. Activity and Toxicity 
PZQ is the only drug available for treatment of all forms of schistosomiasis on a 
large scale50, 51. 60-90% cure rate (no detectable eggs) can be reached when the patient 
is treated with a single 40 mg/kg oral dose of PZQ. Although this is an excellent result, 
100% cure rate is rare. This number may be overestimated, because of the insensitive 
method.46 Furthermore, praziquantel is active against adult schistosomes, but it has no 
activity against the juvenile schistosomula, the young developmental stages of the 
parasite. This is a key factor in the frequently observed treatment ‘failures’ in areas 
endemic for schistosomiasis.52 
Praziquantel was demonstrated to have low toxicity in mice, rats, rabbits, and 
dogs in the acute toxicity, chronic toxicity, and carcinogenicity tests.53 Clinical trials 
confirmed the safety of PZQ on vital organs. Some mild and transient side effects, such 
as headache, gastrointestinal disturbance, insomnia and myalgia, disappear within 24 
hours.54 
1.6.2. Mechanism of action (MOA) 
The precise MOA of PZQ has not been fully identified.55 The proposed targets of 
PZQ are the Ca2+ ion channels56, specifically, the Cavβ ion channel subunit of 
schistosome57. PZQ promotes the muscular paralysis and calcium ions influx in S. 
mansoni.58 Another mechanism of PZQ is the disruption of schistosomal tegument which 
exposes the parasite antigens at the worm’s surface.55, 59 
1.6.3. Drug resistance 
Resistance to PZQ in Egypt60 and Senegal61 due to the intensive application is 
contentious62-64. Under the laboratory condition, S. mansoni has the potential to develop 
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drug resistance to PZQ. After three doses of 300 mg/kg of PZQ were given during 28 to 
37 days of infection, 93% of the seventh passage of S. mansoni survived65. In the long 
run, lacking development of an alternative drug may have serious consequences since 
PZQ is the only drug that is available on the market for mass treatment of 
schistosomiasis66, 67. 
1.7 Aryl hydantoins and antischistosomal activity 
The introduction of PZQ in the 1980s led to decisions to abandon the 
development of many promising antischistosomal agents that were discovered in the 
same period. One of these was AH01 (also called Ro 13- 3978), the lead compound 
from a series of aryl hydantoins that were investigated in some detail at Hoffmann La-
Roche68-71.  
Some characteristics of AH01 justify it as a compelling antischistosomal 
prototype. First, AH01 is easily synthesized in a one-step procedure68, 71. Second, AH01 
has a good pharmacokinetic profile with an elimination half-life in excess of 40 hours in 
experimental animals. Third, as reported by Link and Stohler71, AH01 has high oral 
efficacy against all three major schistosome species – S. mansoni, S. haematobium and 
S. japonicum in a range of animal models. AH01 had a single oral dose ED50 of 26 
mg/kg in S. mansoni-infected mice (adult worms). In this same schistosome mouse 
model, PZQ is considerably less effective against adult S. mansoni, with reported ED50 
values ranging from 172 to 202 mg/kg71, and it has no significant activity against juvenile 
stages of the parasite. In contrast, AH01 has significant activity against the juvenile 
stage of the parasite; in S. mansoni-infected mice (juvenile worms), AH01 had a single 
oral dose ED50 of 140 mg/kg. Moreover, AH01 is schistosome specific as this aryl 
hydantoin had no activity in mice infected with either the intestinal fluke E. caproni or 
with the liver fluke F. hepatica. Finally, in a preliminary in vivo acute toxicity experiment, 
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Link and Stohler71 observed no apparent toxicity following administration of a single 
1250 mg/kg dose of AH01 to mice.  
AH01 has no effect on ex vivo S. mansoni. Despite the high in vivo 
antischistosomal efficacy of AH01, this aryl hydantoin at concentrations up to 100 μg/ml 
(345 μM) over an incubation period of 48 hours had no activity against adult S. mansoni. 
Thus, ex vivo S. mansoni seems to tolerate very high concentrations of AH01. On host 
immunology, PZQ kills fewer adult S. mansoni worms in T-cell deprived mice than in 
immunologically intact controls72.  
AH01 also has antiandrogenic properties. This series of aryl hydantoins 
produced antiandrogenic side effects in the host68, a not unexpected outcome given their 
close structural similarity to the antiandrogenic drug nilutamide. Keiser recently 
demonstrated73 that nilutamide, but not the three structurally diverse androgen receptor 
(AR) antagonists flutamide, bicalutamide, and cyproterone acetate, has weak, but 
measurable, antischistosomal activity in S. mansoni-infected mice. As phylogenetic 
evidence indicates that schistosome species do not appear to have AR’s74, these data 
indicate that for aryl hydantoins, the structural requirements for antischistosomal efficacy 
and AR binding interactions are divergent.  
In this dissertation, I have further studied the antischistosomal and 
antiandrogenic properties of AH01. Administration of 100 mg/kg oral dose of AH01 to 
adult and juvenile Schistosoma mansoni infected mice produced 95 and 64% total worm 
burden reductions, confirming its high activity against adult worms, and demonstrating 
that AH01 is also effective against juvenile infections. AH01 had no measurable 
interaction with the androgen receptor in a ligand competition assay. This work provides 
the foundation for future exploration and discovery of aryl hydantoins with low 
cytotoxicities and promising in vivo antischistosomal activities. 
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A number of AH01 analogs were designed and synthesized to maximize 
structural diversity guided by incorporation of substructures and functional groups known 
to diminish ligand-AR interactions. Although many of the compounds were inactive or 
weakly active, AR11, AR43, AR62, and AR64 had shown worm burden reduction (WBR) 
values >90%. 
It was also discovered that urea carboxylic acid UC00, the product formed by 
hydrolysis of the hydantoin substructure of AH01, has substantial in vivo 
antischistosomal efficacy. A single 100 mg/kg oral dose of UC00 administered to S. 
mansoni-infected mice reduced adult WBR by 67%. However, like AH01, UC00 at 
concentrations up to 100 μg/mL (325 μM) had no measurable effect on ex vivo S. 
mansoni. We also found that UC00 at concentrations up to 30 μM was not cytotoxic to 
rat skeletal myoblast L6 cells. Thus, it was suggested that the relatively high 
antischistosomal efficacy, low cytotoxicity, and good physicochemical properties (Log D 
of 3.1 and PSA of 78 Å) of UC00 make this urea carboxylic acid an attractive starting 
point for optimization. In this respect, we have synthesized a small library of urea 
carboxylic acid analogs that are now undergoing biological testing. 
The symmetrical N,N’-diaryl urea AR33 had been tested in S. mansoni-infected 
mice. AR33 was a side product formed in the synthesis of the aryl hydantoins. A single 
oral dose of AR33 (100 mg/kg) administered to S. mansoni-infected mice reduced adult 
WBR by 40%, data which indicate that this N,N’-diaryl urea is more effective than the 
lead N,N’-diaryl urea MMV66585275. These data provide the basis to move forward with 
further optimization of these N,N’-diaryl ureas. In vitro and in vivo antischistosomal 
activities were evaluated for the diaryl urea library. 
Overall, we have investigated the synthesis and antischistosomal activity of three 
classes of compounds. Specifically, this dissertation is outlined as follows: 
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 Chapter 2 discusses antischistosomal and antiandrogenic properties of aryl 
hydantoin AH01. 
 Chapter 3 focuses on the SAR of the antischistosomal aryl hydantoin AH01. 
 Chapter 4 presents the procedure for synthesis of a library of urea carboxylic 
acid analogs. 
 Chapter 5 lays out the in vitro and in vivo antischistosomal activities of diaryl 
ureas analogs. 
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Antischistosomal versus Antiandrogenic Properties of Aryl Hydantoin AH01 
 
Abstract 
In the early 1980s, the antischistosomal aryl hydantoin AH01 (Ro 13-3978), a close 
structural analogue of the androgen receptor antagonist nilutamide, was discovered.  
Administration of 100 mg/kg oral doses of AH01 to mice infected with adult and juvenile 
Schistosoma mansoni produced 95 and 64% total worm burden reductions, confirming 
its high activity against adult worms, and demonstrating that AH01 is also effective 
against juvenile infections.  AH01 had no measureable interaction with the androgen 
receptor in a ligand competition assay, but it did block dihydrotestosterone-induced cell 
proliferation in an androgen-dependent human prostate cancer cell line. For AH01, 
nilutamide, and three closely related aryl hydantoin derivatives, there was no correlation 
between antischistosomal activity and androgen receptor interaction. 
2.1. Introduction 
Schistosomiasis is a neglected but widespread tropical disease caused by infection 
with parasitic blood flukes. Schistosoma mansoni, S. haematobium, and S. 
japonicumare the most widely distributed species and cause the highest disease burden, 
particularly in sub-Saharan Africa.1-3 Praziquantel (PZQ) is the only drug available for 
treatment of this disease, and it is active against adult schistosomes, but has little 
activity against the juvenile schistosomula, the young developmental stages of the 
parasite.2-4 Should serious praziquantel drug resistance arise, there are no viable 
alternatives to this drug.  Even so, drug discovery for schistosomiasis has languished.  
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The introduction of PZ in 1982 likely led to decisions to abandon the development of 
a number of promising antischistosomal agents that were discovered in the same time 
period.  One of these was AH01 (Ro 13-3978), the lead compound from a series of aryl 
hydantoins that were investigated in some detail at Hoffmann La-Roche.5-8 A number of 
these aryl hydantoins had high oral efficacy in schistosome animal models,8 but they 
also produced antiandrogenic side effects in the host,5 a not unexpected outcome given 
the close structural similarity of these aryl hydantoins to the antiandrogenic drug 
nilutamide (Figure 2.1.). We recently demonstrated9 that nilutamide, but not the three 
structurally diverse androgen receptor (AR) antagonists flutamide, bicalutamide, and 
cyproterone acetate, has antischistosomal activity.  As phylogenetic evidence indicates 
that schistosome species do not appear to have ARs,10 these data led us to hypothesize 
that for aryl hydantoins and related heterocycles, the structural requirements for 
antischistosomal efficacy and AR binding interactions are divergent. 
Based on the limited elucidation of the structure-activity-relationship of this aryl 
hydantoin compound series,8 we began to test this hypothesis by the synthesis8, 11 of 
AH01, its imino isostere AH02, and two derivatives (AH03 and AH04) incorporating 
nitrile functional groups (present in bicalutamide and other antiandrogens) known to 
import high AR binding affinity.12 I now present my initial characterization of the 


































Nilutamide, X = NO2, Y = O
AH01, X = F, Y = O
AH02, X = F, Y = NH
AH03, X = CN, Y = O




AH01-AH04 were obtained using a previously reported procedure. 
The synthesis of 380 mg of AH01 (Scheme 2.1.) to initiate biological studies was 
successfully carried out in one step. It was obtained in 66 % yield by high-temperature 
reactions of 1-fluoro-4-iodo-2-(trifluoromethyl)benzene and hydantoin with cuprous oxide 
in DMF.  Although effective for a first delivery, some important areas for further 
improvement were identified. An improved synthesis was thus pursued to (1) minimize 
the side product; and (2) simplify the work up procedure; (3) improve yield. 
The optimized synthesis produced 15.021 g of AH01 in 90 % yield. The new 
procedure involved an efficient way to remove copper using sg to provide the crude 
mixture without the formation of hydrolysis side product AR37. A successive 
recrystallization from ethanol/H2O and ethyl acetate/hexane provided AH01 with the 
required purity. The formation of dimethylamine was reduced by replacing the solvent 



















2.3. Results and Discussion 
2.3.1. Ligand competition scintillation proximity assay (Figure 2.2.) 
Interaction of the aryl hydantoins with the AR was characterized by a ligand 
competition scintillation proximity assay13 using a hexahistadine-tagged AR-ligand 
binding domain (LBD).  As expected, for the homologous DHT competition experiment, 
we measured a low IC50 value of 76 nM, similar to the previously reported13 value of 57 
nM. Nilutamide and AH03 had IC50 values of 7.4 and 1.5 µM, respectively, whereas the 
other aryl hydantoins had IC50 values > 27 µM.  The binding competition observed for 
nilutamide and AH03 is consistent with previous data demonstrating that AR ligands with 
aryl nitro or nitrile functional groups can form ion-dipole interactions with R752 in the AR 
ligand-binding domain.12 
2.3.2. LNCaP cell proliferation. 
To put the AR ligand competition data in context, we assessed the effects of the aryl 
hydantoins on androgen-dependent LNCaP C-33 human prostate cancer cells.14 As 
expected, DHT significantly induced LNCaP cell proliferation, and this was blocked by 
the antiandrogen bicalutamide (p<0.0001) (Figure 2.3.).  Similarly, AH01 and AH02 
blocked DHT-induced LNCaP cell proliferation (p<0.001), but these compounds had no 
effect on basal cell growth. Conversely, nilutamide, AH03, and AH04 alone stimulated 
LNCaP cell growth (p<0.001), and for nilutamide, addition of DHT decreased (p<0.05) 
cell proliferation.  These data indicate that nilutamide, AH03, and AH04 are AR agonists 
in this cell line.  This is consistent with previous data15 revealing that nilutamide acts as 
an AR agonist in LNCaP cells, presumably as a consequence of the T868A mutation in 
the ligand-binding domain of the AR expressed in this cell line.   It is also possible that 
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DHT may trigger a shutoff mechanism after maximal cell proliferation, consistent with 
previous results that LNCaP cells can respond to androgens in a biphasic concentration-
dependent response.16, 17 For these hydantoins, the apparent discrepancies between the 
ligand competition scintillation proximity assay and LNCaP cell proliferation data may 
also be due to differential antagonistic effect on tetrameric complex dissociation, AR 
dimerization, nuclear translocation and AR interaction with androgen response elements 
in LNCaP cells.18, 19 Thus, androgen-sensitive LNCaP C-33 cells may not be the ideal 
screen to assess the androgenic/antiandrogenic properties of aryl hydantoins.   
2.3.3. In vivo antischistosomal activities against S. mansoni 
In vivo (Table 2.1.) antischistosomal activities against S. mansoni were assessed as 
previously described.9 Single 100 mg/kg oral doses of AH01 and AH02 administered to 
S. mansoni-infected mice on day 49 post-infection (adult worms) afforded respective 
total worm burden reductions of 95 and 93%, confirming the previously reported8 high 
activities (ED50s of 38 and 37 mg/kg for AH01 and AH02) of these compounds.  In this 
same schistosome mouse model, PZQ has an ED50 value of 172 mg/kg.4 Similarly, 
administration of 100 and 200 mg/kg doses of AH01 and AH02 to S. mansoni-infected 
mice on day 21 post-infection (juvenile worms) afforded respective total worm burden 
reductions of 64/88 and 51/88%; this clearly demonstrates that aryl hydantoins, unlike 
PZ, have significant (p < 0.05) activity against the juvenile stage of the parasite.  In 
contrast to the high in vivo efficacies and lack in vivo toxicity that we observed for AH01 
and AH02, administration of single 200 mg/kg oral doses of AH03 and AH04 to S. 
mansoni-infected or uninfected mice led to the death of 60-100% of all animals within 4-
5 days post-treatment.  The observed toxicity of these two aryl hydantoins, the lack of 
apparent in vivo toxicity for nilutamide in this same experiment,9 and the lack of 
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interaction of AH04 with the AR, suggests that the in vivo toxicity of these aryl hydantoin 









Table 2.1.  Effects of single oral doses of AH01 and AH02 administered to mice 









Vehicle control 1* 
Vehicle control 2* 
Vehicle control 3* 
- 27.9 ± 12.5 - 
- 17.4 ± 5.1 - 





100 6.3 ± 4.3‡ 64† 
200 3.0 ± 1.9¶ 88† 
AH02 
100 8.5 ± 6.8‡ 51 
200 3.3 ± 3.3¥ 88† 
Nilutamide§ 100 - 5 
 200 - 22 
 
Adult 
AH01 100 1.5 ± 1.9¶ 95† 
AH02 100 1.3 ± 1.3‡ 93† 
Nilutamide§ 100 - 31 
PZ§ 100 - 18 
 
 
*3% ethanol and 7% Tween 80 solubilizing vehicle 
¶versus vehicle control 1 
‡versus vehicle control 2 
¥versus vehicle control 3 
†p < 0.05 from the Kruskal-Wallis test comparing the medians of the responses between 
the treatment and control groups  
































Figure 2.3. Effects of aryl hydantoins on DHT-induced LNCaP cell proliferation.  
Bars represent the mean ± SE of the average of 2-4 sets of independent duplicate 








In summary, we confirmed the high antischistosomal efficacy of AH01 and 
demonstrated that this aryl hydantoin is also effective against juvenile infections.  
Further, AH01 had no measurable interaction with the AR in a ligand competition assay, 
but it did block DHT-induced cell proliferation in androgen-dependent human prostate 
cancer LNCaP cells.  For AH01, nilutamide, and the other aryl hydantoins, there was no 
correlation between antischistosomal activity and androgen receptor interaction. 
Although previous investigations6 demonstrate that AH01 produces schistosome 
worm lesions similar to those seen following PZ treatment, the molecular mechanism of 
action of this or related aryl hydantoins is unknown.  However, based on our data, their 
antischistosomal properties do not seem to derive from interactions with the host AR.  
Finally, it is interesting to note that although schistosome species do not appear to have 
ARs10, Fantappié et al.20 discovered an expressed schistosome gene encoding the 
mitochondrial enzyme NADH ubiquinone oxidoreductase subunit 5 by screening a S. 
mansoni cDNA library with a human AR cDNA probe.  This mitochondrial enzyme is 
thought to underlie the observed inhibition of S. mansoni growth by high concentrations 
of testosterone and dehydroepiandresterone.20, 21 
2.5. Experimental 
2.5.1. General.   
Melting points are uncorrected. 1D 1H and 13C NMR spectra were recorded on a 500 
MHz spectrometer using CDCl3 or DMSO-d6 as solvents. All chemical shifts are reported 
in parts per million (ppm) and are relative to internal (CH3)4Si (0 ppm) for 1H and CDCl3 
(77.2 ppm) or DMSO-d6  (39.5 ppm) for 13C NMR.  EI GC-MS data were obtained using a 
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quadrapole mass spectrometer with 30 m DB-XLB type columns and a He flow rate of 1 
mL/min.  Silica gel (sg) particle size 32−63 μm was used for all flash column 




To a solution of 5,5-dimethylhydantoin (338 mg, 2.64 mmol) and Cu2O (143 mg, 1.00 
mmol) in DMF (10 mL) was added 1-fluoro-4-iodo-2-(trifluoromethyl)benzene (580 mg, 
2.00 mmol). After it was heated under reflux for 24 h, the solvent was evaporated in 
vacuo. After addition of ammonium hydroxide (10 mL) and H2O (10 mL), the resulting 
precipitate was filtered and purified by chromatography (silica gel, hexane:EtOAc, 2:1) to 
afford 3-[4-fluoro-3-(trifluoromethyl)phenyl]-5,5-dimethylimidazolidine-2,4-dione as a 
white solid (380 mg, 66%). 
New method 
To a solution of 5,5-dimethylimidazolidine-2,4-dione (9.70 g, 76 mmol) and Cu2O 
(4.10 g, 29 mmol) in DMA (280 mL) was added 1-fluoro-4-iodo-2-
(trifluoromethyl)benzene (16.60 g, 57 mmol).The reaction mixture was heated at 160 oC 
for 42 h and cool to rt. After addition of ethyl acetate (250 mL), the resulting precipitation 
(copper) was removed by filtration. The solvent was then filtered through silica gel to 
remove copper and the resulting cake was washed with ethyl acetate (100 mL). 
Evaporation of the filtrate gave a crude product which was further purified by successive 
crystallization from a mixture of ethanol (20 mL) and H2O (500 mL) and a mixture of ethyl 
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acetate (10 mL) and hexane (200 mL) to afford 3-[4-fluoro-3-(trifluoromethyl)phenyl]-5,5-
dimethylimidazolidine-2,4-dione as a white solid (15.021 g, 90 %). 
1H NMR (500 MHz, DMSO-d6) δ 1.41 (s, 6H), 7.66 (t, J = 9.7 Hz, 1H), 7.81 (ddd, J = 
7.5, 4.5, 2.7 Hz, 1H), 7.90 (dd, J = 6.6, 2.5 Hz, 1H), 8.66 (s, 1H). 
13C NMR (125 MHz, DMSO-d6) δ 24.59, 57.95, 116.72 (qd, J = 32.9, 13.4 Hz), 
117.70 (d, J = 21.7 Hz), 122.24 (q, J = 272.5 Hz), 125.68 (q, J = 4.8 Hz), 128.90 (d, J = 
3.3 Hz), 133.55 (d, J = 9.2 Hz), 153.69, 157.56 (dd, J = 254.6, 2.4 Hz), 176.10. 












Figure 2.4. GC spectrum of AH01 
  






















Figure 2.5. MS spectrum of AH01  


























2.5.3. Ligand competition scintillation proximity assay 
To each well of a 96-well Ni-chelate-coated Flashplate® was added 80 μL of 5 μM 
AR-LBD in the assay buffer (25 mM HEPES, pH 7.2, 50 mM NaCl, 0.01% NP-40, 20 µM 
dihydrotestosterone (DHT), 2% DMSO). After 60 min incubation, the protein solution was 
discarded followed by washes with assay buffer. Then, 40 μL of serial diluted aryl 
hydantoins in assay buffer containing 10% DMSO were added into each well followed by 
addition of 40 μL of 20 nM [3H]-DHT in assay buffer. The final assay solutions contained 
5% DMSO. After sealing the plates and equilibrating for 18 h at 4 °C, radiocounts were 
measured and IC50 values were calculated. 
2.5.4. LNCaP cell proliferation. 
LNCaP cells (passage number between 39 to 42) were plated at a density of 5×104 
or 6×104 cells/well in 6-well plates for 72 h in a regular RPMI 1640 culture medium 
containing 5% fetal bovine serum (FBS) which was maintained at 37 °C in a humidified 
atmosphere of 5% CO2. This was followed by continued cell culture for 48 h in a steroid-
reduced medium consisting of phenol red-free RPMI 1640 containing 5% 
charcoal/dextran-treated FBS (v/v), 2 mM glutamine, and 50 μg/mL gentamicin.  Cells 
were then exposed for an additional 72 h to 10 µM test compounds (from 10 mM DMSO 
stock solutions) with or without DHT (10 nM) after which time cell numbers were counted 
and cell growth relative to that of control cells was determined.  
2.5.5. In vivo antischistosomal activities against S. mansoni 
Mice were infected with ca. 80 S. mansoni cercariae on day 0 followed by 
administration of single 100 and 200 mg/kg oral doses of test compounds dissolved or 
suspended in a solubilizing 3% ethanol and 7% Tween 80 vehicle to groups of four to 
36 
 
five mice on day 21 post-infection (juvenile stage) and on day 49 post-infection (adult 
stage).  At 28 days post-treatment, animals were sacrificed by the CO2 method and 
dissected to assess total worm reductions.   
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Revisiting the SAR of the Antischistosomal Aryl Hydantoin AH01 
 
Abstract 
The aryl hydantoin Ro 13-3978 (AH01) was identified in the early 1980's as a 
promising antischistosomal lead compound.  However, this series of aryl hydantoins 
produced antiandrogenic side effects in the host, a not unexpected outcome given their 
close structural similarity to the antiandrogenic drug nilutamide.  Building on the known 
SAR of this compound series, we now describe a number of analogs of AH01 designed to 
maximize structural diversity guided by incorporation of substructures and functional 
groups known to diminish ligand-androgen receptor interactions. The principal SAR 
insight (Figure 3.1.) was that the hydantoin core of AH01 is required for high 
antischistosomal activity.  We identified several compounds with high antischistosomal 
efficacy that were less antiandrogenic than AH01. These data provide direction for the 




















The introduction of Praziquantel (PZQ) in 1982 likely led to decisions to abandon 
the development of a number of promising antischistosomal agents that were discovered 
in the same time period. One of these was AH01 (Figure 3.2.), the lead compound from 
a series of aryl hydantoins that were investigated in some detail at F. Hoffmann La-
Roche1-4. As reported by Link and Stohler4, AH01 has high oral efficacy against all three 
major schistosome species – S. mansoni, S. haematobium and S. japonicum in a range 
of animal models. Confirming these data, we found5 that AH01 had single oral dose ED50 
values of 15 and 140 mg/kg against adult and juvenile S. mansoni in a mouse model.  In 
this same schistosome mouse model, PZQ is considerably less effective against adult S. 
mansoni, with reported ED50 values ranging from 172 to 202 mg/kg4, and it has no 
significant activity against juvenile stages of the parasite. Despite the high in vivo 
antischistosomal efficacy of AH01, we found that this aryl hydantoin at concentrations up 
to 170 µM had almost no effect on cultured adult S. mansoni5. Data generated so far 
indicate that active metabolites do not account for the striking difference between the in 
vitro and in vivo antischistosomal activity of AH015.   
However, this series of aryl hydantoins produced antiandrogenic side effects in 
the host1, a not unexpected outcome given their close structural similarity to the 
antiandrogenic drug nilutamide. We recently demonstrated6 that nilutamide, but not the 
three structurally diverse androgen receptor (AR) antagonists flutamide, bicalutamide, 
and cyproterone acetate, has weak, but measurable, antischistosomal activity in S. 
mansoni-infected mice. As phylogenetic evidence indicates that schistosome species do 
not appear to have AR’s7, these data led us to hypothesize that for aryl hydantoins and 
related heterocycles, the structural requirements for antischistosomal efficacy and AR 



















Highlights from the SAR of this aryl hydantoin compound series conducted by 
Roche4 are: 1) a combination of halogens (F, Cl) and/or CF3 groups at positions 3 and 4 
of the phenyl ring were optimal; 2) EDG groups such as methoxy and dimethylamino at 
these same positions diminished activity; 3) 4-imino derivatives were active; and 4) 
some N1-substituted analogs were active. 
Building on this foundation, we now describe a number of AH01 analogs (Tables 
3.1.-3.4.) designed to maximize structural diversity guided by incorporation of 
substructures and functional groups known to diminish ligand-AR interactions. For 
example, several target compounds maintain the 5,5-dimethylhydantoin core of AH01 
and involve incorporation of sulfonamide (AR57 and AR17), phenethyl (AR18), aromatic 
halogens (AR06, AR27, AR31) and C=N bonds (AR04, AR08, AR43, AR48, AR52, 
AR53, AR55), functional groups and structural elements demonstrated to abolish or 
diminish AR ligand affinity8-12. The final set of target compounds maintain the 4-fluoro-3-
trifluoromethylphenyl substructure of AH01 in heterocycle variants of the 5,5-
dimethylhydantoin substructure: succinimide AR16, urea AR36, oxolactam AR56, 
oxazolidinedione AR23, ring-expanded hydantoins AR32 and AR51, and hydantoin 
transpositional isomer AR58. Hydantoins analogous to AR58 had relatively weak AR 




Table 3.1.  Antiandrogenic, and antischistosomal data for N1-substituted 4-fluoro-
3-trifluoromethylphenyl hydantoins 
 
Compd R LAPC4IC50 (µM)f S. mansoni WBR (%) x 100 mg/kg pog 
AH01 H 4.4 95h 
AR11 CH3 1.3 93 
AR62 CH2CH3 0.14 98 
AR63   CH2CONH2 agonist 25 
AR13   CH2CN 0.29 91 
AR18   (CH2)2C6H5 2.4 54 
AR57 SO2CH3 6.3 19 
AR17 SO2C6H5 4.3 44 
 
 
fCells were then exposed to 10 nM DHT for 24 h in the presence of varying 
concentrations of test compounds. 
gGroups of five S. mansoni-infected NMRI mice were treated on day 49 post-infection 
with compounds dissolved or suspended in SSV.  At 28 days post-treatment, animals 
were sacrificed and dissected to assess total worm burden reduction (WBR). p<0.05 
from the Kruskal–Wallis test comparing the medians of the responses between the 
treatment and control groups. 












Table 3.2.  Antiandrogenic, and antischistosomal data for N3-substituted aryl 
hydantoins 
 
Compd X LAPC4IC50 (µM)f S. mansoni WBR (%)1 x 100 mg/kg 
pog 
Nilutamide NO2 0.60/ 0.45 31h 
AR05 H 6.0 80 
AR06 Cl 1.3 75i 
AR59 CH3 >10 4.8 
AR22 CN 3.7 10 
AR54 CON(CH3)2 9.1 30 
AR64 CF2H ≥10 94 
AR53 H 3.8 1.8 
AR43 CF3 4.5 100 
AR55  1.3 17 
AR08  H 9.6 38 
AR52 CF3 >10 0 
AR48   >10 42 
AR28   4.2 56 
 
a-gsee Table 3.1.footnotes. 
hdata from Keiser et al.6  




Table 3.3.  Antiandrogenic, and antischistosomal data for 5-substituted 4-fluoro-3-
trifluoromethylphenyl hydantoins 
 
Compd X, Y LAPC4IC50 (µM)f S. mansoniWBR (%)1 x 100 mg/kg pog 
AR07b H, H 1.8 0 
AR19b CH3, H >10 66 




AR29 (CH2)4 0.99 61 
AR30 (CH2)5 4.2 42 
AR35 --------- 3.5 0 
 




Table 3.4.  Antiandrogenic, and antischistosomal data for 4-fluoro-3-
trifluoromethylphenyl hydantoinheterocyle variants. 
 
Compd LAPC4IC50 (µM)f S. mansoni WBR (%)1 x 100 mg/kg pog 
AR16 0.91 42 
AR23 2.1 11 
AR56 >10 0 
AR36 8.1 59 
AR58 2.8 0 
AR32 >10 51h 
AR51 6.9 19 
AR37 3.1 67 
 





N1-alkyl and aralkyl hydantoins AR11, AR62, AR63, AR13, AR18 and 
sulfonamides AR57 and AR17 were obtained by N-alkylation and sulfonylation of AH01 
according to the methods of Van Dort and Jung12 and Jung et al.8 (Scheme 3.1.).  
Carboxyurea AR37 was obtained in high yield by hydrolysis of AH01 with aq. NaOH 
followed by acidification with dilute HCl.  
Target compounds AR59, AR22, AR54, AR43, AR55, AR52, and AR48  were 
obtained in variable yields by high-temperature reactions of the corresponding aryl 
iodides (4-iodo-1-methyl-2-(trifluoromethyl)benzene, 2-fluoro-5-iodobenzonitrile, 2-fluoro-
5-iodo-N,N-dimethylbenzamide, 4-iodo-2-(trifluoromethyl)pyridine, 4-iodoquinoline, 5-
iodo-2-(trifluoromethyl)pyridine and 2-iodopyrazine) and hydantoin (5,5-
dimethylimidazolidine-2,4-dione) with cuprous oxide13, 14 in DMA (Scheme 3.2.).   
Reactions between aryl iodide (1-fluoro-4-iodo-2-(trifluoromethyl)benzene) and 
spirohydantoin (1,3-diazaspiro[4.5]decane-2,4-dione) or succinimide (3,3-
dimethylpyrrolidine-2,5-dione) under these same conditions afforded AR30 and AR16, 
respectively (Scheme 3).  Similarly, AR64 was obtained by copper-catalyzed coupling of 
aryl bromide (4-bromo-2-(difluoromethyl)-1-fluorobenzene) and hydantoin (5,5-
dimethylimidazolidine-2,4-dione), whereas AR28 was obtained by alkylation of benzyl 
bromide (4-(bromomethyl)-1-fluoro-2-(trifluoromethyl)benzene) with hydantoin (5,5-
dimethylimidazolidine-2,4-dione) (Scheme 3.4.).  Compound AR36 was obtained in a 
palladium-catalyzed N-arylation reaction15 between aryl iodide (1-fluoro-4-iodo-2-
(trifluoromethyl)benzene) and imidazolidin-2-one (4,4-dimethylimidazolidin-2-one) 
(Scheme 3.3.)16.   
N-arylation via copper (II) acetate promoted cross-coupling17-19 of boronic acids 
(pyridin-3-ylboronic acid and pyridin-4-ylboronic acid) with hydantoin (5,5-
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dimethylimidazolidine-2,4-dione) afforded AR08 and AR53; the same cross-coupling 
reaction between boronic acid ((4-fluoro-3-(trifluoromethyl)phenyl)boronic acid) and 1,3-
oxazolidine-2,4-dione or bicyclic hydantoin (tetrahydro-1H-pyrrolo[1,2-c]imidazole-
1,3(2H)-dione) afforded AR23 and AR35, respectively (Scheme 3.5.). 
Compounds AR19B, AR34, AR40 and AR29 were obtained in a two-step 
sequence4, 11, 20 by reactions between aryl isocyanate (1-fluoro-4-isocyanato-2-
(trifluoromethyl)benzene) and α-amino acids  (alanine, (R)-2-amino-2-phenylacetic acid, 
2-amino-3-hydroxy-2-methylpropanoic acid, and 1-aminocyclopentane-1-carboxylic acid)  
in aq. NaOH to form the corresponding urea carboxylic acids that then cyclized to the 
hydantoins when exposed to 2-4 M HCl at 110 °C (Scheme 3.6.).  Compounds AR32 
and AR51 were obtained by parallel two-step reactions between isocyanate (1-fluoro-4-
isocyanato-2-(trifluoromethyl)benzene)  and-amino acids (3-amino-3-methylbutanoic 
acid and 3-amino-2,2-dimethylpropanoic acid).  In some instances, the acyclic urea 
carboxylic acid reaction intermediates precipitated from the initial reactions after 
acidification, but these were not purified, and were converted directly to the desired 
hydantoin reaction products.  For almost all of these reactions, small amounts of the 
insoluble symmetrical N,N-diarylurea derived from isocyanate (1-fluoro-4-isocyanato-2-
(trifluoromethyl)benzene)  were formed. 
Oxolactam AR56 was obtained by cyclization of the anion of benzyl amide ester 
(methyl 2-(2-(4-fluoro-3-(trifluoromethyl)phenyl)acetamido)-2-methylpropanoate)  in a 
Dieckmann-type condensation21; it was obtained from the corresponding acid chloride 
(2-(4-fluoro-3-(trifluoromethyl)phenyl)acetyl chloride) (Scheme 3.7.).The key 
intermediate in the synthesis of AR58 was gem-dimethyl α-amino amide (2-((4-fluoro-3-
(trifluoromethyl)phenyl)amino)-2-methylpropanamide), which was obtained in a one-pot 
free radical multicomponent reaction22 from aniline (4-fluoro-3-(trifluoromethyl)aniline).  
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Exposure of this amino amide to 2,6-diisopropylphenyl isocyanate at high temperature23 
effected carbonylativering closure to hydantoin AR58. Compounds AH01, AR05, AR06, 






aReagents and conditions: (a) NaH, DMF, rt, 0.5 h, then MeI, rt, 2h; (b) NaH, THF, 0 °C 
to rt, 3 h, then EtI, rt, 3d; (c) NaH, THF, 0 °C to rt, 3 h, then 2-bromoacetamide, rt, 3d; (d) 
NaH, DMF, rt, 0.5 h, then 2-bromoacetonitrile, rt, 2h; (e) NaH, DMF, rt, 0.5 h, then 2-
bromoethylbenzene, rt, 2h; (f) NaH, THF, 0 °C to rt, 0.5 h, then MeSO2Cl, rt, 3d; (g) NaH, 
DMF, rt, 0.5 h, then benzenesulfonyl chloride, rt, 2 h; (h) 2 M NaOH, rt, 4 h, then 2 M 














aReagents and conditions: (a) Cu2O, DMA, 160 °C; 24 h; (b) Cu2O, DMF, 160 °C; 48 h 














aReagents and conditions: (a) Cu(OAc)2, MeOH, O2, 70 °C; 12 h; (b) Cu(OAc)2, pyridine, 















(a) 1 M TiCl4 in CH2Cl2, formamide, acetone, 0 °C, 1 h, then Zn, 50% H2O2 in formamide, 
0 °C, 3 h; (b) 2,6-diisopropylphenyl isocyanate, toluene, 250 °C, 5 bar, 10 min, MW; (c) 
methyl 2-amino-2-methylpropanoate HCl, Et3N, THF, rt, 12 h; (d) NaH, THF, rt, 12 h, 





3.4. Results and Discussion 
3.4.1 Antiandrogenic and antischistosomal activities 
We now consider the in vitro antiandrogenic and in vivo antischistosomal 
properties of these AH01 analogs. The former was assessed by inhibition of 
dihydrotestosterone (DHT)-dependent cell growth in the LAPC4 cell line, a cell line with 
a wild-type androgen receptor (AR), and the latter by measuring worm burden reduction 
(WBR) in S. mansoni-infected mice.  Contrary to our expectation based on the previous 
SAR for this compound class, we did not observe decreased antiandrogenic potencies 
for sulfonamides AR57 and AR17 and phenethyl AR18 (Table 3.1.).  N1-Substitution with 
small alkyl (AR11, AR62) groups increased antiandrogenic potencies, most strongly for 
the latter.  Incorporation of nitrile (AR13) and carboxamide (AR63) functional groups into 
the N1-alkylsubstructure had very different effects; the former was a potent antiandrogen 
whereas the latter had no antiandrogenic properties and was instead a weak AR agonist.  
Similar to that of AH01, N1-substituted hydantoins AR11, AR62, and AR13 had high 
antischistosomal activities; of the remaining compounds in this series, only AR18 had 
significant, but weak antischistosomal activity.   
The antiandrogenic and antischistosomal properties of the N3-substituted aryl 
hydantoins exhibit several interesting trends (Table 3.2.).  Replacing the 4-F in AH01 
with a NO2 (Nilutamide) or Cl (AR06) increased antiandrogenic potency, whereas a H 
(AR05) or Me (AR59) at this same position decreased antiandrogenic potency.  Of 
these, hydantoins AR05 and AR06 had high antischistosomal activities, similar to 
previously reported data4.  Replacing the 3-trifluoro in AH01 with a nitrile (AR22) had no 
effect on antiandrogenic potency and abolished antischistosomal activity.  However, 
replacing the 3-trifluoromethyl in AH01 with a tertiary carboxamide (AR54) or 
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difluoromethyl (AR64) decreased antiandrogenic potency, and the latter had high 
antischistosomal activity.  Hydantoin AR28, the benzyl derivative of AH01, had similar 
antiandrogenic potency and significantly reduced antischistosomal activity compared to 
the latter. As we had anticipated based on known SAR for antiandrogenic hydantoins, 
we observed decreased antiandrogenic potencies for some of the derivatives with 
aromatic C=N bonds; these included pyridines AR08 and AR52 and pyrazine AR48.  
However, the only one of the C=N containing hydantoins to have high antischistosomal 
activity was AR43, the 4-pyridyl derivative with a trifluoromethyl group.    
As the data in Table 3.3. illustrate, our initial foray into the SAR of the 5-position 
of AH01 did not bear much fruit. The principle insight gained was to note that replacing 
one, but not both, of the methyl groups decreases antiandrogenic activity. Of these 
derivatives, only AR29 had significant antischistosomal activity, but this 5,5-
spirocyclopentyl derivative also had relatively potent antiandrogenic activity. Bicyclic 
hydantoin AR35 reveals that connecting the 5 and N1-position with a pyrrolidine 
substructure completely abolished antischistosomal activity and offered no improvement 
in antiandrogenic activity.  Finally, the data in Table 3.4. shows that the hydantoin core 
of AH01 is required for high antischistosomal activity. Of these, only cyclic urea AR36 
and urea carboxylic acid AR37 had significant antischistosomal activity.  The latter is the 
hydrolysis product of AH01 and is formed in small quantities when AH01 is administered 
at high doses. Interestingly, as reported by Link and Stohler4, the methyl ester of AR37 
has good antischistosomal activity. 
3.5. Summary 
The SAR of the 5-substituted aryl hydantoins reveals that replacing one of the 
methyl groups with a hydrogen atom decreases antiandrogenic activity and retains 
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significant antischistosomal activity.  Investigation of heterocycle variants showed that 
the hydantoin core of AH01 is required for high antischistosomal activity.   
3.6. Experimental Section 
3.6.1. General.   
Melting points are uncorrected. 1D 1H and 13C NMR spectra were recorded on a 
500 MHz spectrometer using CDCl3 or DMSO-d6 as solvents. All chemical shifts are 
reported in parts per million (ppm) and are relative to internal (CH3)4Si (0 ppm) for 1H 
and CDCl3 (77.2 ppm) or DMSO-d6  (39.5 ppm) for 13C NMR.  EI GC-MS data were 
obtained using a quadrapole mass spectrometer with 30 m DB-XLB type columns and a 
He flow rate of 1 mL/min.Silica gel (sg) particle size 32−63 μm was used for all flash 
column chromatography.  Reported reaction temperatures are those of the oil bath.   
 
5,5-Dimethyl-3-(pyridin-3-yl)imidazolidine-2,4-dione (AR08).  
 
To a solution of 5,5-dimethylimidazolidine-2,4-dione (1.792 g, 14mmol) and Cu(OAc)2 
(181 mg, 1mmol) in methanol (50 mL) was added pyridin-3-ylboronic acid (1.23 g, 10 
mmol) under O2.The mixture was heated at 70 oC overnight. The solvent was then 
filtered through silica gel to remove copper and the resulting cake was washed with 
methanol (100 mL). Evaporation of the filtrate gave a crude product which was further 
purified by successive crystallizations from diethyl ether (10 mL) and saturated Na2CO3 
(10 mL) to afford AR08 as a white solid (1.258 g, 61%).  
mp 160–162 °C; 
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1H NMR (CDCl3) δ 1.56 (s, 6H), 6.85 (s, 1H), 7.43 (dd, J = 4.4, 7.8 Hz, 1H), 7.84 (d, J = 
8.3 Hz, 1H), 8.62 (d, J = 4.4 Hz, 1H), 8.78 (s, 1H); 
13C NMR (CDCl3) δ 25.22, 58.87, 123.57, 128.78, 133.15, 146.79, 148.65, 154.72, 
175.79.  





To a solution of 3-(4-fluoro-3-(trifluoromethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione 
(700 mg, 2.4 mmol) in DMF was added NaH (87 mg, 3.6 mmol) under Ar. The mixture 
was stirred at rt for 30 min and then iodomethane (514 mg, 3.6 mmol) was added 
dropwise. After stirring for 2 h, the mixture was evaporated in vacuo to give a residue 
which was extracted with brine (30 mL) and EtOAc (3 x 30 mL). The combined organic 
phase was washed with brine (2 x 30 mL) and dried over MgSO4. After removal of the 
solvents, the residue was purified by chromatography (sg, hexane:EtOAc, 4:1) to afford 
AR11 as a white solid (580 mg, 79%). 
mp 110–112 °C; 
1H NMR (CDCl3) δ 1.51 (s, 6H), 2.98 (s, 3H), 7.29 (t, J = 9.3 Hz, 1H), 7.66-7.69 (m, 1H), 
7.77(d, J = 6.3 Hz, 1H); 
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13C NMR (CDCl3) δ 22.28, 24.68, 61.22, 117.48 (br), 118.96 (qd, J = 33.6, 13.9 Hz), 
122.03 (q, J = 272.5 Hz), 124.80 (br), 128.07(d, J = 3.6 Hz), 131.23 (d, J = 8.6 
Hz),153.44, 158.48 (q, J = 258.2 Hz), 175.14. 






To a solution of 3-(4-fluoro-3-(trifluoromethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione 
(700 mg, 2.4 mmol) in DMF was added NaH (116 mg, 4.8 mmol) under Ar. The mixture 
was stirred at rt for 30 min and then 2-bromoacetonitrile (578 mg, 4.8 mmol) was added 
dropwise. After stirring for 2 h, the mixture was evaporated in vacuo to give a residue 
which was extracted with brine (30 mL) and EtOAc (3 × 30 mL). The combined organic 
phase was washed with brine (2 × 30 mL) and dried over MgSO4. After removal of the 
solvents, the residue was purified by chromatography (sg, hexane:EtOAc, 2:1) to afford 
AR13 as a white solid (573 mg, 72%).  
mp147–149 °C; 
1H NMR (CDCl3) δ 1.65 (s, 6H), 4.37 (s, 2H), 7.32 (t, J = 9.3 Hz, 1H), 7.66-7.69 (m, 1H), 
7.75 (dd, J = 2.4, 5.9 Hz, 1H); 
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13C NMR (CDCl3) δ 22.75, 27.14, 62.11, 114.73, 117.81 (d, J = 22.1 Hz), 119.28 (qd, J = 
33.6, 13.9 Hz), 121.90 (q, J = 273.0 Hz), 124.89 (q, J = 1.9 Hz), 127.28 (d, J = 4.4 Hz), 
131.27 (d, J = 9.6 Hz), 153.13, 158.83 (q, J = 257.2 Hz), 173.71.  
Anal Calcd for C14H11F4N3O2: C, 51.07; H, 3.37; N, 12.76; Found: C, 51.29; H, 3.60; N, 
12.52. 
 
1-[4-Fluoro-3-(trifluoromethyl)phenyl]-3,3-dimethylpyrrolidine-2,5-dione (AR16 29) 
 
To a solution of 3,3-dimethylpyrrolidine-2,5-dione (1.71 g, 13.5 mmol) and Cu2O (0.74 g, 
5.2 mmol) in DMF (15 mL) was added 1-fluoro-4-iodo-2-(trifluoromethyl)benzene (3.0 g, 
10.3 mmol) and the mixture was heated to reflux for 48 h.  After cooling to rt, the solvent 
was evaporated in vacuo. After addition of conc. ammonium hydroxide (20 mL) and H2O 
(15 mL), the resulting precipitate was filtered and purified by chromatography (sg, 
hexane:EtOAc, 5:1) to afford AR16 as a white solid (1.39 g, 46%).  
mp 134–136 °C; 
1H NMR (CDCl3) δ 1.44 (s, 6H), 2.74 (s, 2H), 7.33 (t, J = 9.3 Hz, 1H), 7.53-7.56 (m, 1H), 
7.62(d, J = 5.9 Hz, 1H); 
13C NMR (CDCl3) δ 25.60, 40.23, 43.62, 117.67 (d, J = 22.1 Hz), 119.15 (qd, J = 34.6, 
13.4 Hz), 121.95 (q, J = 272.5 Hz), 125.33 (br), 128.0 (d, J = 3.8 Hz), 131.9 (d, J = 8.6 
Hz),158.89 (d, J = 258.6 Hz), 174.20, 181.67. 
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To a solution of 3-(4-fluoro-3-(trifluoromethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione 
(700 mg, 2.4 mmol) in DMF (15 mL) was added NaH (87 mg, 3.6 mmol) under Ar. The 
mixture was stirred at rt for 30 min and then benzenesulfonyl chloride (639 mg, 3.6mmol) 
was added dropwise. After stirring for 2 h, the mixture was evaporated in vacuo to give a 
residue which was extracted with brine (30 mL) and EtOAc (3 × 30 mL). The combined 
organic phase was washed with brine (2 × 30 mL) and dried over MgSO4. After removal 
of the solvents, the residue was purified by chromatography (sg, hexane:EtOAc, 4:1) to 
afford AR17 as a white solid (739 mg, 71%). 
mp 153–155 °C; 
1H NMR (CDCl3) δ 1.92 (s, 6H), 7.27 (t, J = 9.4 Hz, 1H), 7.57-7.71 (m, 5H), 8.13 (d, J = 
8.3 Hz, 2H); 
13C NMR (CDCl3) δ 24.26, 66.75, 117.80 (d, J = 22.2 Hz),119.29 (qd, J = 34.1, 13.9Hz), 
121.77 (q, J = 272.5 Hz), 125.14 (br), 126.46 (d, J = 3.8 Hz),128.73, 129.16, 131.54 (d, J 
= 9.1 Hz), 134.59, 138.32, 150.57, 158.99 (d, J = 259.6 Hz), 172.81. 
66 
 
Anal Calcd for C18H14F4N2O4S·0.7H2O: C, 48.80; H, 3.50; N, 6.32; Found: C, 48.44; H, 





To a solution of 3-(4-fluoro-3-(trifluoromethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione 
(700 mg, 2.4 mmol) in DMF (15 mL) was added NaH (87 mg, 3.6 mmol) under Ar. The 
mixture was stirred at rt for 30 min and then 2-bromoethylbenzene (670 mg, 3.6 mmol) 
was added dropwise. After stirring for 2 h, the mixture was evaporated in vacuo to give a 
residue which was extracted with brine (30 mL) and EtOAc (3 × 30 mL). The combined 
organic phase was washed with brine (2 × 30 mL) and dried over MgSO4. After removal 
of the solvents, the residue was purified by chromatography (sg, hexane:EtOAc, 4:1) to 
afford AR18 as a white solid (410 mg, 43%). 
mp 98–100 °C; 
1H NMR (CDCl3) δ 1.39 (s, 6H), 3.05 (t, J = 7.8 Hz, 2H), 3.53 (t, J = 8.3 Hz, 2H), 7.24-
7.34 (m, 6H), 7.69-7.72 (m, 1H), 7.78 (dd, J = 2.4, 6.9 Hz, 1H); 
13C NMR (CDCl3) δ 23.12, 35.34, 42.23, 61.86, 117.46 (d, J = 22.2 Hz),118.94 (qd, J = 
33.1, 13.9Hz), 122.04 (q, J = 272.0 Hz), 124.72 (br), 126.81,128.69, 128.81, 131.14 (d, J 
= 8.5 Hz),138.23, 153.62, 158.49 (d, J = 258.2 Hz), 174.94. 
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Anal Calcd for C20H18F4N2O2: C, 60.91; H, 4.60; N, 7.10; Found: C, 60.70; H, 4.89; N, 
7.26. 
 
5-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-fluorobenzonitrile (AR22 12) 
 
To a solution of 5,5-dimethylimidazolidine-2,4-dione (0.674 g, 5.3 mmol) and Cu2O (290 
mg, 2 mmol) in DMA (4 mL) was added 2-fluoro-5-iodobenzonitrile (1.0 g, 4.1 mmol). 
After it was heated to 160 oC for 48 h, the solvent was evaporated in vacuo. After 
addition of EtOAc (100 mL), the resulting precipitate was filtered and the filtrate was 
concentrated and purified by chromatography (sg, EtOAc) followed by recrystallization 
from ethanol:H2O (1:20) to afford AR22 as a white solid (768 mg, 77%).  
mp 145–147 °C; 
1H NMR (CDCl3) δ 1.56 (s, 6H), 6.70 (s, 1H), 7.33 (t, J = 8.8 Hz, 1H), 7.78-7.81 (m, 1H), 
7.84 (dd, J = 2.4, 5.4 Hz, 1H); 
13C NMR (CDCl3) δ25.15, 58.83, 102.08 (d, J = 17.3 Hz), 112.99, 117.08 (d, J = 21.1 Hz), 
128.52 (d, J = 3.4 Hz), 130.48, 132.28 (d, J = 8.6 Hz), 154.41, 161.74 (d, J = 261.0 Hz), 
175.47. 







To a solution of 5,5-dimethyloxazolidine-2,4-dione (903 mg, 7.0 mmol) and Cu(OAc)2 (90 
mg, 0.5 mmol) in methanol (25 mL) was added (4-fluoro-3-
(trifluoromethyl)phenyl)boronic acid (1.04 g, 5.0mmol) under O2.The mixture was heated 
at 70 oC overnight. After cooling to rt, the solvent was evaporated in vacuo. The residue 
was purified by chromatography with successive elution with hexane and EtOAc 
followed by crystallization from ethanol:H2O (1:10) to afford AR23 as a white solid (421 
mg, 29%). 
mp 174–176 °C; 
1H NMR (CDCl3) δ 1.70 (s, 6H), 7.34 (t, J = 8.8 Hz, 1H), 7.69-7.72 (m, 1H), 7.79 (dd, J = 
2.4, 5.9 Hz, 1H); 
13C NMR (125.7 MHz, CDCl3) δ 23.74, 83.80, 117.99 (d, J = 22.1 Hz), 119.48 (qd, J = 
34.1, 13.9 Hz), 121.81 (q, J = 272.5 Hz), 124.53 (br),127.12 (d, J = 3.4 Hz),130.89 (d, J 
= 9.1 Hz),152.54, 159.01 (dq, J = 259.6, 1.9 Hz), 174.32. 






A mixture of 4-(bromomethyl)-1-fluoro-2-(trifluoromethyl)benzene (1.552 g, 6.0 mmol), 
5,5-dimethylimidazolidine-2,4-dione (647 mg, 5.1 mmol) and K2CO3 (2.004 g,  14.5 
mmol) in DMA (12.5 mL) was stirred at 85 oC for 24 h. The mixture was extracted with 
EtOAc (3 × 50 mL) and H2O (50 mL).  The organic phase was combined, dried, and 
evaporated in vacuo to give a residue which was further purified by chromatography (sg, 
EtOAc:hexane, 1:3) followed by crystallization from H2O (5 mL) to afford AR28 as a 
white solid (1.16 g, 75%). 
mp 86–87 oC; 
1H NMR (DMSO-d6) δ 1.32 (s, 6H), 4.63 (s, 2H), 7.50 (dd, J = 10.7, 8.6 Hz, 1H), 7.56-
7.63 (m, 1H), 7.66 (d, J = 7.0 Hz, 1H), 8.46 (s, 1H); 
13C NMR (DMSO-d6) δ 24.53, 39.91, 58.03, 116.53 (qd, J = 32.4, 12.6 Hz), 117.55 (d, J 
= 20.7 Hz), 122.47 (q, J = 272.0 Hz), 126.07 (q, J = 4.7 Hz), 133.99, 134.04 (d, J = 5.3 
Hz), 154.91, 158.10 (dq, J = 253.2, 2.3 Hz), 177.22. 





Step 1.To a solution of 1-aminocyclopentane-1-carboxylic acid (1.161 g, 9.0 mmol) in 1 
M NaOH (15 mL) was added a solution of 1-fluoro-4-isocyanato-2-
(trifluoromethyl)benzene (1.83 g, 8.9 mmol) in CH3CN (10 mL) at 0 oC dropwise. The 
mixture was stirred at 0 oC for 3 h and then warmed to rt overnight. The reaction mixture 
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was adjusted to pH=1.0 by 32% HCl and concentrated in vacuo. Step 2. The resulting 
precipitate was collected by filtration and the solid was then suspended in 4 M HCl (50 
mL) and heated at 110 °C overnight. After the reaction mixture was cooled to rt, the 
resulting precipitate was filtered and crystallized from diethyl ether to give AR29 as a 
white solid (660 mg, 23%). 
mp 151–152 oC; 
1H NMR (DMSO-d6) δ 1.67-1.92 (m, 6H), 2.01-2.16 (m, 2H), 7.65 (dd, J = 10.5, 9.0 Hz, 
1H), 7.78-7.84 (m, 1H), 7.90 (dd, J = 6.6, 2.6 Hz, 1H), 8.86 (s, 1H); 
13C NMR (DMSO-d6) δ 24.82, 37.58, 67.49, 116.86 (qd, J =33.2, 13.4 Hz), 117.89 (d, J = 
21.9 Hz), 122.43 (q, J = 272.4 Hz), 125.72, 129.14, 133.61 (d, J = 9.0 Hz), 154.16, 
157.65 (d, J = 253.1 Hz), 176.55.  
Anal Calcd for C14H12F4N2O2: C, 53.17; H, 3.82; N, 8.86. Found: C, 52.89; H, 4.00; N, 




To a solution of 1,3-diazaspiro[4.5]decane-2,4-dione (840 mg, 5.0 mmol) and Cu2O (290 
mg, 2.0 mmol) in DMA (20 mL) was added 1-fluoro-4-iodo-2-(trifluoromethyl)benzene 
(1170 mg, 4.0 mmol). After it was heated at 160 oC for 24 h, the solvent was evaporated 
in vacuo. The residue was purified by chromatography (sg. EtOAc) to afford AR30 as a 
white solid (917 mg, 69%). 
mp 213–215 oC; 
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1H NMR (DMSO-d6) δ 1.25-1.40 (m, 1 H) 1.58 (br s, 3H) 1.64-1.83 (m, 6H) 7.65 (t, J = 
9.7 Hz, 1H), 7.77 – 7.84 (m, 1H) 7.89 (d, J = 6.35 Hz, 1H) 9.05 (br s, 1H); 
13C NMR (DMSO-d6) δ 20.93, 24.56, 33.33, 61.27, 116.88 (qd, J = 33.0, 13.3), 117.9 (d, 
J = 22.0), 122.4 (q, J = 272.5), 125.87 (d, J = 4.1), 129.03, 133.76 (d, J = 9.2), 154.27, 
157.7 (d, J = 254.7), 175.64.  





Step 1. To a solution of 3-amino-3-methylbutanoic acid (585 mg, 5.0mmol) in 2 M NaOH 
(5 mL) was added 1-fluoro-4-isocyanato-2-(trifluoromethyl)benzene (1.95 g, 9.5 mmol).  
After it was stirred at rt for 4 h, the reaction mixture was filtered to remove the insoluble 
N,N-diarylurea side product, and the filtrate was adjusted to pH=1.0 with 2 M HCl and 
concentrated. Step 2. The residue was suspended in 2 M HCl (50 mL) and then heated 
at 110 °C for 2 h. After the reaction mixture was cooled to rt, the resulting precipitate was 
filtered and washed with H2O (20 mL) to give AR32 as a white solid (477 mg, 31%). 
mp 225–226 oC;  
1H NMR (DMSO-d6) δ 1.31 (s, 6H), 2.74 (s, 2H), 7.53–7.64 (m, 2H), 7.71 (dd, J = 6.7, 
2.4 Hz, 1H), 8.18 (s, 1H); 
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13C NMR (DMSO-d6) δ 28.11, 44.32, 48.22, 116.88 (qd, J = 32.6, 13.3 Hz), 117.68 (d, J 
= 21.5 Hz), 122.54 (q, J = 272.3 Hz), 128.60 (d, J = 4.8 Hz), 132.82 (d, J = 3.5 Hz), 
136.61 (d, J = 9.1 Hz), 152.51, 158.16 (d, J = 254.0 Hz), 169.81.  
Anal Calcd for C13H12F4N2O2·0.5 H2O: C, 49.85; H, 4.18; N, 8.94. Found: C, 49.79; H, 
4.51; N, 8.81. GC-MS purity: 100% 
 
(R)-3-[4-Fluoro-3-(trifluoromethyl)phenyl]-5-phenylimidazolidine-2,4-dione (AR34) 
Step 1. To a solution of (R)-2-amino-2-phenylacetic acid (1.057 g, 7.0 mmol) in 1 M 
NaOH (10 mL) was added 1-fluoro-4-isocyanato-2-(trifluoromethyl)benzene (2.05 g, 10 
mmol) in CH3CN (5 mL) at 0 oC dropwise. The mixture was stirred at 0 oC for 3 h and 
then 1,4-dioxane (10 mL) was added according to the method of Cooper et al24. After 
stirring at rt overnight, the reaction mixture was adjusted to pH=2 by 32% HCl and 
concentrated in vacuo. Step 2. The resulting precipitate was successively crystallized 
from EtOH:H2O (1:10) and EtOAc:hexane (1:10) to give (R)-2-[3-[4-fluoro-3-
(trifluoromethyl)phenyl]ureido]-2-phenylacetic acid as a white solid (1.661 g, 67%), 818 
mg of which was then suspended in 4 M HCl (50 mL) and heated at 110 °C overnight. 
After the reaction mixture was cooled to 0 oC, the resulting precipitate was filtered to give 
AR34 as a white solid (678 mg, 87%). 
mp 166–168 oC;  
1H NMR (DMSO-d6) δ 5.37 (s, 1H), 7.33-7.54 (m, 5H), 7.67 (dd, J = 10.0, 9.7 Hz, 1H), 
7.78-7.88 (m, 1H), 7.92 (dd, J = 6.7, 2.5Hz, 1H), 9.10 (s, 1H).  
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13C NMR (DMSO-d6) δ 60.36, 117.01 (qd, J =32.8, 13.5 Hz), 118.05 (d, J = 21.8 Hz), 
122.40 (q, J = 272.7 Hz), 125.89, 127.55, 128.76, 128.89, 128.97 (d, J = 3.4 Hz), 133.80 
(d, J = 9.3 Hz), 135.55, 155.33, 157.85 (d, J = 258.6 Hz), 171.60.  






To a solution of tetrahydro-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione (538 mg, 3.8 
mmol), Cu(OAc)2 (1.370 g, 7.6 mmol) and pyridine (900 mg, 11.4 mmol) in CH2Cl2 (38 
mL) was added [4-fluoro-3-(trifluoromethyl)phenyl]boronic acid (2.359 g, 11.3 mmol). 
After stirring at rt for 7 days, the solvent was removed in vacuo. The residue was purified 
by chromatography (sg, EtOAc) and then crystallized from hexane to afford AR35 as a 
white solid (443 mg, 39%). 
mp 146–148 oC; 
1H NMR (CDCl3) δ 1.78-1.93 (m, 1H), 2.06-2.30 (m, 2H), 2.32-2.45 (m, 1H), 3.37 (ddd, J 
= 11.6, 8.5, 4.6 Hz, 1H), 3.80 (dt, J = 11.5, 7.8 Hz, 1H), 4.27 (dd, J = 9.4, 7.5 Hz, 1H), 
7.29 (t, J = 9.3 Hz, 1H), 7.60-7.68 (m, 1H), 7.74 (dd, J = 6.2, 2.6 Hz, 1H); 
13C NMR (DMSO-d6) δ 26.38, 26.50, 45.30, 62.94, 116.77 (qd, J = 33.1, 13.5 Hz), 
117.87 (d, J = 21.8 Hz), 122.20 (q, J = 272.0 Hz), 125.68, 128.89 (d, J = 3.4 Hz), 133.59 
(d, J = 9.4 Hz), 157.66 (d, J = 255.0 Hz), 158.26, 172.45. 
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To a solution of 4,4-dimethyl-2-imidazolidinone (500 mg, 4.4 mmol), Cs2CO3 (2.460 g, 
7.5 mmol), Xantphos (108 mg, 0.19 mmol) and Pd2(dba)3 (84 mg, 0.09 mmol) in toluene 
(40 mL) was added 1-fluoro-4-iodo-2-(trifluoromethyl)benzene (1.270 g, 4.4 mmol). The 
reaction mixture was stirred at 90 oC for 12 h under Ar. Evaporation gave a crude 
product which was purified by washing with water (25 mL), chromatography (sg, EtOAc), 
and recrystallizion from hexane to afford AR36 as a white solid (939 mg, 77%). 
mp 147–148 oC; 
1H NMR (DMSO-d6) δ 1.28 (s, 6H), 3.64 (s, 2H), 7.39 (s, 1H), 7.45 (t, J = 9.8 Hz, 1H), 
7.72 (dt, J = 9.2, 3.6 Hz, 1H), 8.05 (dd, J = 6.4, 2.9 Hz, 1H); 
13C NMR (DMSO-d6) δ 28.20, 50.57, 57.07, 114.69 (q, J = 5.2 Hz), 116.22 (qd, J = 32.1, 
12.9 Hz), 117.29 (d, J = 21.3 Hz), 122.30 (d, J = 7.7 Hz), 122.66 (q, J = 272.3 Hz), 
137.58, 153.26 (d, J = 247.5 Hz), 157.02. 





2-[3-[4-Fluoro-3-(trifluoromethyl)phenyl]ureido]-2-methylpropanoic acid (AR37). 
 
Hydantoin AH01 (1.20 g, 4.1 mmol) was added to 2 M NaOH (40 mL). The reaction 
mixture was stirred at rt for 4 h, and then quenched with 2 M HCl (50 mL). The 
precipitate was filtered and rinsed by H2O (20 mL) and then dried to afford AR37 as a 
white solid (1.20 g, 95%). 
mp 196.5–197.5 °C; 
1H NMR (DMSO-d6) δ 1.43 (s, 6H), 6.61 (s, 1H), 7.37 (t, J = 9.8 Hz, 1H), 7.47-7.50 
(m,1H), 7.96-7.97 (m, 1H), 8.87 (s, 1H), 12.44 (s, 1H);  
13C NMR (DMSO-d6) δ 25.42, 55.13, 115.12 (d, J = 5.0 Hz), 116.45 (qd, J = 31.6, 12.8 
Hz), 117.65 (d, J = 21.5 Hz), 122.85 (q, J = 272.1 Hz), 123.42 (d, J = 7.8 Hz), 137.34, 
153.32 (d, J = 246.9 Hz), 154.37, 176.31. 






Step 1.To a solution of 2-amino-3-hydroxy-2-methylpropanoic acid (537 mg, 4.5 mmol) 
in dioxane (23 mL) was added 1-fluoro-4-isocyanato-2-(trifluoromethyl)benzene (8.10 g, 
39.5) under Ar. After the reaction mixture was stirred at 80 oC for 6 h, it was cooled to rt, 
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diluted with CH2Cl2 (25 mL) and extracted with 2 M NaOH (3 × 25 mL). After the 
combined aq. layers were separated and filtered to remove the insoluble N,N-diarylurea 
side product, the filtrate was acidified with 2 M HCl (100 mL) and concentrated. Step 2. 
The residue was suspended in 2 M HCl (50 mL) and then heated at 110°C for 4 h. After 
the reaction mixture was cooled to rt, the resulting precipitate was collected by filtration 
to give AR40 (370 mg, 27%) as a white solid. 
mp 166–168 °C; 
1H NMR (DMSO-d6) δ 1.30 (s, 3H), 3.43 (d, J = 10.7 Hz, 1H), 3.67 (d, J = 11.2 Hz, 1H), 
7.66 (t, J = 10.3 Hz, 1H), 7.76-7.77 (m, 1H), 7.81 (d, J = 6.3, 1H), 8.52 (s, 1H);  
13C NMR (DMSO-d6) 18.97, 63.52, 65.38, 117.00 (q, J = 32.5 Hz), 118.07 (d, J = 22.0 
Hz), 122.40 (q, J = 273.0 Hz), 125.20, 129.15, 133.29 (d, J = 9.2 Hz), 154.78, 157.61 (d, 
J = 254.2 Hz), 175.04.  




To a solution of 5,5-dimethylimidazolidine-2,4-dione (776 mg, 6.1 mmol) and Cu2O (288 
mg, 2.0 mmol) in DMA (30 mL) was added 4-iodo-2-(trifluoromethyl)pyridine (750 mg, 
2.8 mmol). After stirring at 140 oC for 24 h, the solvent was evaporated in vacuo to give a 
crude product which was further purified by sg chromatography using successive elution 
with hexane and EtOAc to afford AR43 as a white solid (674 mg, 90%).  
mp 195–197 oC; 
77 
 
1H NMR (DMSO-d6) δ 1.43 (s, 6H), 7.95 (dd, J = 5.4, 1.9 Hz, 1H), 8.14 (d, J = 1.8 Hz, 
1H), 8.87 (d, J=5.4 Hz, 1H), 8.89 (br s, 1H);  
13C NMR (DMSO-d6) δ 24.61, 57.82, 116.17, 121.39 (q, J = 274.3 Hz), 122.29, 141.72, 
146.94 (q, J = 34.1 Hz), 151.15, 152.68, 175.71. 
Anal Calcd for C11H10F3N3O2: C, 48.36; H, 3.69; N, 15.38. Found: C, 47.97; H, 4.00; N, 




To a solution of 5,5-dimethylimidazolidine-2,4-dione (1.28 g, 10.0 mmol) and Cu2O 
(357.5 mg, 2.5 mmol) in DMA (20 mL) was added 2-iodopyrazine (1.00 g, 4.9 mmol). 
The reaction mixture was then heated to 140 oC for 24 h. After solvent removal in vacuo, 
the crude product was purified by sg chromatography using successive elutions with 
hexane, EtOAc, and ethanol. After removal of the solvents in vacuo, the residue was 
crystallized from a mixture of ether (0.5 mL) and hexane (10 mL). The resulting 
precipitate was collected by filtration to give A48 as a pale yellow solid (210 mg, 21%).  
mp 149-151 oC;  
1H NMR (DMSO-d6) δ 1.44 (s, 6H), 8.66-8.90 (m, 4H); 
13C NMR (DMSO-d6) δ 24.65, 58.38, 142.76, 143.72, 143.91, 144.38, 153.05, 175.80.  
Anal Calcd for C9H10N4O2; C, 52.42; H, 4.89; N, 27.17. Found: C, 52.34; H, 5.00; 







Step 1. To a solution of 3-amino-2,2-dimethylpropanoic acid hydrochloride (700 mg, 4.6 
mmol) in 2 M NaOH (5 mL) was added 1-fluoro-4-isocyanato-2-(trifluoromethyl)benzene 
(1.95 g, 9.5 mmol), and the reaction mixture was stirred at rt for 4 h. After filtration to 
remove the insoluble N,N-diarylurea side product, the filtrate was adjusted to pH=1.0 
with 2 M HCl and concentrated to afford 3-[3-[4-fluoro-3-(trifluoromethyl)phenyl]ureido]-
2,2-dimethylpropanoic acid (480 mg, 32%) as a white solid.  
1H NMR (DMSO-d6) δ 1.09 (s, 6H), 3.22 (d, J = 6.2 Hz, 2H), 6.25 (t, J = 6.2 Hz, 1H), 7.36 
(t, J = 9.8 Hz, 1H), 7.43-7.53 (m , 1H), 7.95 (dd, J = 6.5, 2.8 Hz, 1H), 8.99 (s, 1H), 12.39 
(s, 1H). 
Step 2. 3-[3-[4-fluoro-3-(trifluoromethyl)phenyl]ureido]-2,2-dimethylpropanoic acid (450 
mg, 1.4 mmol) was suspended in 2 M HCl (50 mL) and then heated at 110 °C for 12 h. 
After the reaction mixture was cooled to rt, the resulting precipitate was filtered and 
washed with saturated NaHCO3 (30 mL) to give AR51 as a white solid (355 mg, 83%). 
mp 214–215 oC; 
1H NMR (DMSO-d6) δ 1.21 (s, 6H), 3.18 (d, J= 2.8 Hz, 2H), 7.52-7.59 (m, 2H), 7.63-7.69 
(m, 1H), 8.11 (s, 1H); 
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13C NMR (DMSO-d6) δ 22.35, 37.39, 46.31, 116.60 (qd, J = 32.9, 13.7 Hz), 117.41 (d, J 
= 21.5 Hz), 122.34 (q, J = 271.9 Hz), 128.34, 133.07 (d, J = 3.5 Hz), 136.42 (d, J = 9.2 
Hz), 153.02, 157.88 (d, J = 253.6 Hz), 175.33. 





To a solution of 5,5-dimethylimidazolidine-2,4-dione (384 mg, 3.00 mmol) and Cu2O (143 
mg, 1.00 mmol) in DMA (10 mL) was added 5-iodo-2-(trifluoromethyl)pyridine (476 mg, 
1.74 mmol), and the mixture was heated to 140 oC for 48 h. After solvent removal in 
vacuo, the crude product was purified by sg chromatography using successive elution 
with hexane and EtOAc. After removal of the solvents in vacuo, the residue was 
crystallized from 20:1 hexane and EtOAc. The resulting precipitate was collected by 
filtration and rinsed with H2O (5 mL) to give AR52 as a white solid (357 mg, 75%).  
mp 173–174 °C; 
1H NMR (DMSO-d6) δ 1.44 (s, 6 H), 8.08 (d, J=8.3 Hz, 1 H), 8.20 (d, J=8.3 Hz, 1 H), 8.80 
(s, 1 H), 8.88 (s, 1 H); 
13C NMR (DMSO-d6) δ 24.80, 58.36, 121.16, 121.61(q, J = 273.9 Hz), 132.27, 135.50, 
144.63  (q, J = 34.4 Hz), 147.43, 153.32,176.10.  







To a solution of 5,5-dimethylimidazolidine-2,4-dione (5.38 g, 42 mmol) and Cu(OAc)2 
(543 mg, 3mmol) in methanol (150 mL) was added pyridin-4-ylboronic acid (3.6 g, 29 
mmol) under O2.The mixture was heated at 70 oC overnight. The solvent was then 
filtered through silica gel to remove copper and the resulting cake was washed with 
methanol (100 mL). Evaporation of the filtrate gave a crude product which was further 
purified by crystallization from a saturated Na2CO3 solution (20 mL) to afford AR53 as a 
white solid (2.8 g, 47%). 
mp 201–203 oC; 
1H NMR (DMSO-d6) δ 1.42 (s, 6H), 7.57 (d, J = 5.6 Hz, 2H), 8.67 (d, J = 6.1 Hz, 2H), 
8.74 (brs, 1H). 
13C NMR (DMSO-d6) δ 24.70, 57.75, 119.62, 139.85, 150.26, 153.08, 175.88. 








To a solution of 5,5-dimethylimidazolidine-2,4-dione (640 mg, 5.0mmol) and Cu2O (259 
mg, 1.8 mmol) in DMA (10 mL) was added 2-fluoro-5-iodo-N,N-dimethylbenzamide (496 
mg, 1.7 mmol). The mixture was then heated to 150 oC for 48 h. Solvent removal in 
vacuo gave a crude product which was further purified by sg chromatography using 
successive elution with hexane, EtOAc and ethanol followed by crystallization from a 
mixture EtOAc:hexane (1:10) to afford AR54 as a white solid (296 mg, 58%). 
mp 166–168 oC; 
1H NMR (DMSO-d6) δ 1.40 (s, 6H), 2.87 (s, 3H), 3.01 (s, 3H), 7.41 (t, J = 9.1 Hz, 1H), 
7.44 (dd, J = 6.0, 2.5 Hz, 1H), 7.51 (ddd, J = 8.9, 4.8, 2.6 Hz, 1H), 8.59 (s, 1H). 
13C NMR (DMSO-d6) δ 24.68, 34.33, 37.85, 57.85, 116.21 (d, J = 23.3 Hz), 124.76 (d, J 
= 20.0 Hz), 127.11 (d, J = 4.7 Hz), 128.69 (d, J = 3.0 Hz), 129.62 (d, J = 8.7 Hz), 153.93, 
156.32 (d, J = 246.5 Hz), 164.45, 176.27. 







To a solution of 5,5-dimethylimidazolidine-2,4-dione (384 mg, 3 mmol) and Cu2O (142 
mg, 1 mmol) in DMA (5 mL) was added 4-iodoquinoline (163 mg, 0.64 mmol). After the 
reaction mixture was heated at 150 oC for 72 h, the solvent was removed in vacuo. The 
residue was purified by sg chromatography using successive elution with hexane, EtOAc 
and ethanol to afford AR55 as a pale yellow solid (101 mg, 62%). 
mp 194–196 oC;  
1H NMR (DMSO-d6) δ 1.50 (s, 3H), 1.57 (s, 3H), 7.61 (d, J = 4.6 Hz, 1H), 7.65-7.76 (m, 
2H), 7.86 (t, J = 7.2 Hz, 1H), 8.15 (d, J = 8.4 Hz, 1H), 8.83 (s, 1H), 9.05 (d, J = 4.6 Hz, 
1H); 
13C NMR (DMSO-d6) δ 24.50, 25.26, 58.77, 121.60, 122.83, 124.72, 127.58, 129.42, 
130.15, 137.08, 148.77, 150.73, 153.60, 176.45. 





Step 1. A mixture of 2-[4-fluoro-3-(trifluoromethyl)phenyl]acetic acid (2.22 g, 10 mmol) 
and SOCl2 (4 mL) was stirred at 80 oC overnight. The reaction mixture was concentrated 
in vacuo to afford 2-[4-fluoro-3-(trifluoromethyl)phenyl]acetyl chloride which was used for 
the next step without further purification. Step 2. To a solution of methyl 2-amino-2-
methylpropanoate HCl salt (1.53 g, 10 mmol) and Et3N (5.0 g, 50 mmol) in THF (47.5 
mL) was added acetyl chloride in THF (2.5 mL), and the reaction mixture was stirred at rt 
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overnight. After filtration to remove insoluble TEA HCl salt, the filtrate was concentrated 
in vacuo. The residue was purified by chromatography (sg, EtOAc:hexane, 1:1) to afford 
methyl 2-[2-[4-fluoro-3-(trifluoromethyl)phenyl]acetamido]-2-methylpropanoate as a white 
solid (1.13 g, 35%).1H NMR (DMSO-d6) δ 1.35 (s, 6H), 3.50 (s, 3H), 3.52 (s, 2H), 7.45 
(dd, J = 10.9, 8.6 Hz, 1H), 7.52-7.61 (m, 1H), 7.63 (d, J = 7.7 Hz, 1H), 8.54 (s, 1H). Step 
3. To a solution of methyl 2-[2-[4-fluoro-3-(trifluoromethyl)phenyl]acetamido]-2-
methylpropanoate (860 mg, 2.68 mmol) in THF (7 mL) was added a suspension of NaH 
(300 mg, 12.5 mmol) in THF (6.4 mL) dropwise under Ar. The reaction mixture was 
stirred at rt for 12 h before quenching with a mixture of acetic acid (1.2 g, 20 mmol) and 
H2O (1 mL). Solvent removal in vacuo gave a crude product which was crystallized from 
hexane to afford AR56 as a white solid (406 mg, 52%). 
mp 217–219 oC; 
1H NMR (DMSO-d6) δ 1.36 (s, 6H), 7.46 (dd, J = 10.8, 8.9 Hz, 1H), 7.83 (s, 1H), 8.30-
8.40 (m, 1H), 8.47 (dd, J = 7.4, 2.2 Hz, 1H), 11.68 (s, 1H). 
13C NMR (DMSO-d6) δ 24.54, 56.49, 98.64, 115.88 (qd, J = 31.8, 12.2 Hz), 116.56 (d, J 
= 20.1 Hz), 122.87 (q, J = 271.4 Hz), 124.55 (q, J = 4.8 Hz), 129.75 (d, J = 3.7 Hz), 
132.87 (d, J = 8.0 Hz), 156.37 (d, J = 250.9 Hz), 170.39, 176.13. 








To a solution of AH01 (700 mg, 2.4mmol) in THF (7.5 mL) was added NaH (100 mg, 4.1 
mmol) in THF (7.5 mL) at 0 oC under Ar. The reaction mixture was then stirred at rt for 
30 min before dropwise addition of methanesulfonyl chloride (410 mg, 3.6mmol). After 
further stirring at rt for 72 h, the reaction was quenched with acetic acid (4 mL). Removal 
of solvents in vacuo gave a residue to which was added H2O (30 mL). The resulting 
precipitate was filtered and crystallized from EtOAc:hexane (1:5) to afford AR57 as a 
white solid (812 mg, 92%). 
mp 207–208 oC; 
1H NMR (CDCl3) δ 1.86 (s, 6H), 3.44 (s, 3H), 7.35 (t, J = 9.2 Hz, 1H), 7.67 (dt, J = 7.4, 
3.5 Hz, 1H), 7.75 (dd, J = 6.1, 2.7 Hz, 1H). 
13C NMR (CDCl3) δ 24.19, 43.53, 66.73, 118.19 (d, J = 22.3 Hz), 119.70 (qd, J = 33.9, 
13.9 Hz), 121.95 (q, J = 272.6 Hz), 125.36 (qd, J = 6.9, 4.5 Hz), 126.56, 131.70 (d, J = 
9.4 Hz), 151.70, 159.31 (d, J = 259.9 Hz), 173.02. 







Step 1. To a mixture of 4-fluoro-3-(trifluoromethyl)aniline (1.791 g, 10 mmol), formamide 
(50 mL) and acetone (25 mL) was added 1 M TiCl4 in CH2Cl2 (12.5 mL) at 0 oC under Ar. 
After 1 h, Zn powder (1.5 g, 23 mmol) was added followed by dropwise addition of 50% 
H2O2 (1.75 mL) in formamide (23.25 mL) over 3 h. The reaction was quenched with H2O 
(25 mL) and adjusted to pH=8 with conc. ammonium hydroxide followed by extraction 
with EtOAc (3 × 50 mL). The combined organic layers were concentrated in vacuo and 
the residue was dissolved in CHCl3 (100 mL). The solution was then washed with H2O (3 
× 25 mL). Evaporation gave a crude product which was further purified by successive 
recrystallizations from a mixture of CH2Cl2 (5 mL) and hexane (1 mL) and a mixture of 
acetic acid (150 mg) and H2O (1 mL) to afford 2-[[4-fluoro-3-
(trifluoromethyl)phenyl]amino]-2-methylpropanamide as a white solid (418 mg, 16%); 1H 
NMR (DMSO-d6) δ 1.35 (s, 6H), 6.18 (s, 1H), 6.71 (dt, J = 9.0, 3.6 Hz, 1H), 6.81 (dd, J = 
6.0, 3.0 Hz, 1H), 7.05 (s, 1H), 7.22 (t, J = 9.8 Hz, 1H), 7.34 (s, 1H); 13C NMR (DMSO-d6) 
δ 25.22, 56.63, 111.09 (q, J = 4.7 Hz), 116.20 (qd, J = 31.5, 13.0 Hz), 117.16 (d, J = 
21.2 Hz), 118.79 (d, J = 7.4 Hz), 122.92 (q, J = 272.0 Hz), 143.20 (d, J = 1.9 Hz), 150.44 
(dq, J = 241.0, 2.4 Hz), 177.13. Step 2. To a solution of 2-[[4-fluoro-3-
(trifluoromethyl)phenyl]amino]-2-methylpropanamide (160 mg, 0.6 mmol) in toluene (5 
mL) was added 2-isocyanato-1,3-diisopropylbenzene (150 µL) using a pipette. After the 
mixture was heated to 250 oC at 5 bar for 10 min under microwave irradiation in a sealed 
tube, the solvent was evaporated in vacuo. The residue was purified by sg 
chromatography eluting successively with CH2Cl2 and acetone:hexane (1:3) to afford 
AR58 as a white solid (108 mg, 62%). 
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mp 193–195 oC; 
1H NMR (DMSO-d6) δ 1.34 (s, 6H), 7.63 (t, J = 9.7 Hz, 1H), 7.71–7.78 (m, 1H), 7.84 (dd, 
J = 6.6, 2.6 Hz, 1H), 11.26 (s, 1H); 
13C NMR (DMSO-d6) δ 23.09, 64.21, 117.25 (qd, J = 32.8, 13.2 Hz), 118.25 (d, J = 21.5 
Hz), 122.18 (q, J = 273.5 Hz), 128.19, 131.44 (d, J = 3.4 Hz), 135.86 (d, J = 9.2 Hz), 
154.99, 157.87 (d, J = 254.8 Hz), 177.14. 





Step 1. To a solution of 2-aminopropanoic acid (2.225 g, 25 mmol) in 1 M NaOH (40 mL) 
was added 1-fluoro-4-isocyanato-2-(trifluoromethyl)benzene (6.15 g, 30 mmol) in CH3CN 
(15 mL) at 0 oC dropwise. The reaction mixture was stirred at 0 oC for 3 h and then 
warmed to rt overnight.  Step 2. The reaction mixture was adjusted to pH=3.0 by 32% 
HCl and concentrated in vacuo. The resulting precipitate was crystallized from 
EtOAc:hexane (1:40) to give 2-[3-[4-fluoro-3-(trifluoromethyl)phenyl]ureido]propanoic 
acid as a white solid (5.157 g, 70%), 1.1 g (3.74 mmol) of which was suspended in 4 M 
HCl (50 mL) and then heated at 110 °C overnight. After the reaction mixture was cooled 
to rt, the resulting precipitate was filtered to afford AR19B as a white solid (845 mg, 
82%).  
mp 153–154 oC; 
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1H NMR (DMSO-d6) δ 1.38 (d, J = 6.9 Hz, 3H), 4.27 (q, J = 6.9 Hz, 1H), 7.65 (t, J = 9.7 
Hz, 1H), 7.76 – 7.83 (m, 1H), 7.87 (dd, J = 6.7, 2.5 Hz, 1H), 8.59 (s, 1H); 
13C NMR (DMSO-d6) δ 16.94, 52.23, 116.73 (qd, J = 32.8, 13.4 Hz), 117.76 (d, J = 21.8 
Hz), 122.23 (q, J = 272.1 Hz), 125.47 (q, J = 5.1 Hz), 128.95 (d, J = 3.5 Hz), 133.43 (d, J 
= 9.3 Hz), 154.84, 157.50 (dq, J = 254.3, 2.1 Hz), 173.81. 





To a solution of 5,5-dimethylimidazolidine-2,4-dione (2.54 g, 19.8 mmol) and Cu2O (1.09 
g, 7.6 mmol) in DMA (30 mL) was added 4-bromo-2-(difluoromethyl)-1-fluorobenzene 
(3.50 g, 15.5 mmol). After the reaction mixture was heated at 160 oC for 24 h, the solvent 
was removed in vacuo. The residue was purified by chromatography (sg, EtOAc) and 
then crystallized successively from hexane (15 mL) and H2O (20 mL) to afford AR64 as 
a white solid (3.43 g, 81%). 
mp 158–159oC; 
1H NMR (DMSO-d6) δ 1.41 (s, 6H), 7.26 (t, J = 54.1 Hz, 1H), 7.51 (t, J = 9.5 Hz, 1H), 
7.59 – 7.68 (m, 1H), 7.72 (dd, J = 6.4, 2.5 Hz, 1H), 8.62 (s, 1H). 
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13C NMR (DMSO-d6) δ 24.60, 57.85, 111.52 (td, J = 236.2, 3.5 Hz), 116.72 (d, J = 21.8 
Hz), 121.46 (td, J = 23.4, 14.0 Hz), 125.75 (d, J = 3.3 Hz), 128.68 (d, J = 3.3 Hz), 131.64 
(d, J = 9.0 Hz), 153.79, 158.38 (dt, J = 251.3, 4.8 Hz), 176.17. 







To a solution of AH01 (1.04 g, 3.6 mmol) in THF (15 mL) was added NaH (163 mg, 6.8 
mmol) in THF (15 mL) at 0 oC under Ar. The mixture was then stirred at rt for 3 h before 
dropwise addition of 2-bromoacetamide (937 mg, 6.8 mmol). The reaction mixture was 
stirred at rt for 72 h before quenching with acetic acid (600 mg, 10 mmol). Solvent 
removal in vacuo gave a residue which was crystallized from CH2Cl2 to afford AR63 as a 
white solid (600 mg, 48%).  
mp 186–187 oC;  
1H NMR (DMSO-d6) δ 1.43 (s, 6H), 3.90 (s, 2H), 7.25 (s, 1H), 7.50 (s, 1H), 7.69 (t, J = 
9.7 Hz, 1H), 7.80-7.86 (m, 1H), 7.90 (dd, J = 6.6, 2.5 Hz, 1H);  
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13C NMR (DMSO-d6) δ 22.04, 41.90, 61.62, 116.72 (qd, J = 32.9, 13.6 Hz), 117.84 (d, J 
= 21.8 Hz), 122.21 (q, J = 272.4 Hz), 125.36 (q, J = 5.0 Hz), 128.74 (d, J = 3.3 Hz), 
133.37 (d, J = 9.3 Hz), 153.50, 157.56 (dq, J = 254.9, 1.9 Hz), 169.63, 175.02. 







To a solution of AH01 (700 mg, 2.4 mmol) in THF (7.5 mL) was added NaH (87 mg, 3.6 
mmol) in THF (7.5 mL) at 0 oC under Ar. The reaction mixture was then stirred at rt for 3 
h before dropwise addition of iodoethane (561 mg, 3.6 mmol). The reaction mixture was 
stirred at rt for 72 h before quenching with acetic acid (600 mg, 10 mmol) and H2O (1 
mL). Solvent removal in vacuo gave a residue which was crystallized from H2O. The 
residue was further purified by chromatography (sg, EtOAc:hexane, 1:4) to afford AR62 
as a white solid (301 mg, 39%).  
mp 90–91 oC; 
1H NMR (CDCl3) δ 1.32 (t, J = 7.2 Hz, 3H), 1.53 (s, 6H), 3.43 (q, J = 7.2 Hz, 2H), 7.29 (t, 
J = 9.4 Hz, 1H), 7.65-7.74 (m, 1H), 7.78 (dd, J = 6.3, 2.6 Hz, 1H). 
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13C NMR (CDCl3) δ 15.14, 23.58, 35.08, 61.97, 117.60 (d, J = 22.1 Hz), 119.11 (qd, J = 
33.6, 13.6 Hz), 122.21 (q, J = 272.5 Hz), 124.95 (q, J = 4.5 Hz), 128.25 (d, J = 3.6 Hz), 
131.34 (d, J = 8.9 Hz), 153.46, 158.60 (d, J = 258.1 Hz), 175.28. 





To a solution of 5,5-dimethylimidazolidine-2,4-dione (568 mg, 4.44 mmol) and Cu2O (240 
mg, 1.68mmol) in DMA (15 mL) was added 4-iodo-1-methyl-2-(trifluoromethyl)benzene  
(1.00 g, 3.5 mmol). After stirring at 160 oC for 12 h, the solvent was evaporated in vacuo 
to give a crude product which was further purified by sg chromatography using 
successive elution with hexane, EtOAc, and EtOH to afford AR59 as a white solid (536 
mg, 54%). 
mp 134–135 oC; 
1H NMR (CDCl3) δ 1.57 (s, 6H), 2.51 (s, 3H), 5.52 (s, 1H), 7.39 (d, J = 8.2 Hz, 1H), 7.50 
(d, J = 7.9 Hz, 1H), 7.70 (s, 1H); 
13C NMR (DMSO-d6) δ 18.43, 24.65, 57.85, 123.92 (q, J = 5.2 Hz), 124.09 (q, J = 273.6 
Hz), 127.54 (q, J = 29.6 Hz), 130.37, 130.41, 132.59, 135.53, 153.85, 176.21. 





3.6.2. Antischistosomal Screen.  
As described by Keiser (2010), cercariae of S. mansoni were obtained from infected 
Biomphalaria glabrata. NMRI mice were infected subcutaneously with approximately 100 
S. mansoni cercariae. At 49 d after infection, groups of four mice were treated with 
single 100 mg/kg oral doses of compounds in a 7% (v/v) Tween 80% and 3% (v/v) 
ethanol vehicle (10 mL/kg).  Untreated mice (n = 8) served as controls.  At 21 d post-
treatment, animals were killed by the CO2 method and dissected.  Worms were removed 
by picking, then sexed and counted.   
 
3.6.3. Androgen-Dependent Cell-based Assay.  
As described by Jones and Diamond (2008), transfected LAPC4 cells were cultured in 
phenolredfree RPMI 1640 media supplemented with antibiotics and 10% FBS.  Cells 
were then exposed to 10 nM DHT for 24 h in the presence of varying concentrations of 
test compounds. Control wells on eachplate included no DHT (base line signal) and DHT 
without test compounds (maximal signal). After 24 h, normalized luciferase signals were 
measured. Nilutamide (N) was used as a positive control.  Mean-effect plots from four 
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Urea carboxylic acid antischistosomal agents 
Abstract 
Urea carboxylic acid AR37, the product formed by hydrolysis of the hydantoin 
substructure of Ro 13-39781, has substantial in vivo antischistosomal efficacy. Base on 
this finding, several efficient synthetic routes were developed to make the first round of 
urea carboxylic acid targets. These methods can be applied to the synthesis of 
structurally diverse AR37 analogs. These urea carboxylic acids could lead to an advance 
in the structure–activity relationship of this class of compounds in antischistosomal 
researches. 
4.1 Introduction 
Schistosomiasis is a tropical parasitic disease2 caused by infections with flukes of 
the genus Schistosoma. Of these, Schistosoma mansoni, S. haematobium, and S. 
japonicum cause the largest public health burden3-5. Praziquantel (PZQ) is the only drug 
available for treatment of this disease6, 7. The high drug pressure from the widespread 
administration of PZQ could lead to problematic drug resistance8, 9.  Even so, drug 
discovery for schistosomiasis has languished10, 11. 
In Chapter 3, I discovered that urea carboxylic acid AR37, the product formed by 
hydrolysis of the hydantoin substructure of Ro 13-39781, has substantial in vivo 
antischistosomal efficacy. Further, investigations by Roche scientists1 revealed that the 
methyl ester of AR37 had a single oral dose ED50 of 62 mg/kg. No other analogs of 





Previously, we showed that a single 100 mg/kg oral dose of AR37 administered 
to S. mansoni-infected mice reduced adult WBR by 67%. However, like Ro 13-3978, 
AR37 at concentrations up to 100 μg/mL (325 μM) had no measurable effect on ex vivo 
S. mansoni. We also found that AR37 at concentrations up to 30 μM was not cytotoxic to 
rat skeletal myoblast L6 cells. Thus, we suggest that the relatively high antischistosomal 
efficacy, low cytotoxicity, and good physicochemical properties (Log D of 3.1 and PSA of 
78 Å) of AR37 indicate that this urea carboxylic acid is an attractive starting point for 
optimization.  
In this respect, we designed the first round of urea carboxylic acid targets. They 
include the primary amide U01, the unsubstituted analog U06, the conformationally-
restricted UC04, the succinamic acid UC05 and the phenylacetamide derivative UC06. 
In UC03, UC07 and UC08, the gem-dimethyl group of AR37 is replaced with the H 
(UC03), cyclopropyl (UC07) and cyclobutyl (UC08) groups. 
4.3 Chemistry 
U06, UC03, UC07, and UC08 were obtained by reaction of phenyl isocyanates 
(1a, 1b) with α-amino acids (2a, 2b, 2c, 2d) in aq. NaOH to form the corresponding urea 
carboxylic acids (Scheme 4.1.). Conformationally-restricted urea UC04 (cyclouracil) was 
obtained by exposure of the Ro 13-3978 with 1-bromo-3-chloropropane according to the 
method of Kawamura et al12 (Scheme 4.2.). U01 was obtained by reaction of conc. 
NH4OH with activated AR37 (Scheme 4.2.). Succinamic acid UC05 was obtained by 
acylation of 4-fluoro-3-trifluoromethylaniline with 2,2-dimethylsuccinic anhydride 
according to the published method13 (Scheme 4.3.). UC06, the phenylacetamide 
derivative of AR37, was obtained by the acylation of 2-amino-2-methyl propanoic acid 







Scheme 4.1.  
 








Scheme 4.2.  
 
(a) 2 M NaOH, rt, 4 h; 
(b) HOBt, EDCI·HCl, DMA, rt, 12 h; 
(c) conc. NH4OH, rt, 1.5 h; 























(a) SOCl2, DMF, CH2Cl2, rt, 12 h; 
(b) 4-fluoro-3-(trifluoromethyl)aniline, DMA, rt, 12 h; 




4.4.  Discussion 
4.4.1. Synthesis of U04 
The proposed mechanism of the formation of UC04 was shown in Figure 4.1. 
The first step was an intermolecular N-alkylation of the hydantoin AR02 to form N1-3-
chloropropyl hydantoin (3a). This hydantoin 3a was further hydrolyzed and then 
intramolecularly alkylated under the basic condition to form UC04. The trace amount of 
NaOH resulted from the hydrolysis of NaH. 
4.4.2. Synthesis of U05 
Two different approaches were explored for the synthesis of succinamic acid 
UC05. One of these approaches was to hydrolyze methyl ester 4a by NaOH to produce 
UC05. However, 1H NMR showed an 1:1 ratio of UC05 and UC09 (Figure 4.2.). They 
were formed by the cyclization of methyl ester 4a and then hydrolysis under basic 
condition. Another approach included acylation of 4-fluoro-3-trifluoromethylaniline with 
2,2-dimethylsuccinic anhydride according to the published method.13 The 1H NMR 
showed a 95% selectivity for UC05 (Figure 4.3.). The crude was crystallized from CH2Cl2 
(10 mL) to afford UC05 (93%) as a white solid. 
4.5 Summary 
Several efficient synthetic routes were developed to make the first round of urea 
carboxylic acid targets. These methods can be applied to the synthesis of structurally 
diverse AR37 analogs. These urea carboxylic acids could lead to an advance in the 





































General.   
Melting points are uncorrected. 1D 1H and 13C NMR spectra were recorded on a 
500 MHz spectrometer using CDCl3 or DMSO-d6 as solvents. All chemical shifts are 
reported in parts per million (ppm) and are relative to internal (CH3)4Si (0 ppm) for 1H 
and CDCl3 (77.2 ppm) or DMSO-d6 (39.5 ppm) for 13C NMR.  EI GC-MS data were 
obtained using a quadrapole mass spectrometer with 30 m DB-XLB type columns and a 
He flow rate of 1 mL/min.  Silica gel (sg) particle size 32−63 μm was used for all flash 
column chromatography.  Reported reaction temperatures are those of the oil bath.   
Synthesis of U01. 
 
3-[4-fluoro-3-(trifluoromethyl)phenyl]-5,5-dimethylimidazolidine-2,4-dione (1.20 g, 
4.1 mmol) was added 2 M NaOH (40 mL). After it was stirred at rt for 4 h, the reaction 
was quenched and adjusted to pH=3.0 with 2 M HCl. The resulting precipitate was 
collected by filtration to give 2-[3-[4-fluoro-3-(trifluoromethyl)phenyl]ureido]-2-
methylpropanoic acid as a white solid (1.20 g, 95%).  
1H NMR (500 MHz, DMSO-d6) δ 1.42 (s, 6H), 6.60 (s, 1H), 7.36 (t, J = 9.8 Hz, 
1H), 7.42 – 7.55 (m, 1H), 7.96 (dd, J = 6.5, 2.8 Hz, 1H), 8.87 (s, 1H), 12.43 (s, 1H). 
To a solution of 2-[3-[4-fluoro-3-(trifluoromethyl)phenyl]ureido]-2-methylpropanoic 
acid(1.2 g, 3.9 mmol) and N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride 
(1.1 g,  5.7 mmol) in DMA (60 mL) was added N-Hydroxy succinimide (552 mg,  4.8 
mmol). After it had been stirred at rt for overnight, the reaction was quenched with H2O 
(300 mL). The resulting precipitate was collected by filtration to give 2,5-dioxopyrrolidin-
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1-yl 2-[3-[4-fluoro-3-(trifluoromethyl)phenyl]ureido]-2-methylpropanoate (560 mg, 35%) 
as a white solid. 
1H NMR (500 MHz, DMSO-d6) δ 1.57 (s, 6H), 2.79 (bs, 4H), 7.07 (s, 1H), 7.38 (t, 
J = 9.7 Hz, 1H), 7.52–7.58 (m, 1H), 7.96 (d, J = 6.1 Hz, 1H), 8.83 (s, 1H). 
The mixture of 2,5-dioxopyrrolidin-1-yl 2-[3-[4-fluoro-3-
(trifluoromethyl)phenyl]ureido]-2-methylpropanoate (560 mg, 1.38 mmol) in 28% wt 
ammonium hydroxide (20 mL) was stirred at rt for 1.5 h. The precipitation was collected 
by filtration and washed with 2 M NaOH (10 mL) to afford 2-[3-[4-fluoro-3-
(trifluoromethyl)phenyl]ureido]-2-methylpropanamideas a white solid (350 mg, 83%) 
1H NMR (500 MHz, DMSO-d6) δ 1.45 (s, 6H), 6.60 (s, 1H), 7.06 (s, 1H), 7.32 (s, 
1H), 7.35 (t, J = 9.8 Hz, 1H), 7.41–7.51 (m, 1H), 7.97 (dd, J = 6.6, 2.7 Hz, 1H), 9.10 (s, 
1H). 
13C NMR (125 MHz, DMSO-d6) δ 25.05, 55.53, 114.71 (d, J = 4.3 Hz), 116.20 (qd, 
J = 31.8, 12.8 Hz), 117.41 (d, J = 21.3 Hz), 122.68 (q, J = 272.5 Hz), 123.00 (d, J = 7.8 
Hz), 137.46 (d, J = 2.6 Hz), 152.96 (d, J = 246.8 Hz), 153.78, 176.81. 
mp 205–206 oC 
Anal Calcd for C12H13F4N3O2: C, 46.91; H, 4.26; N, 13.68; Found: C, 46.82; H, 
4.32; N, 13.35 




To a solution of 2-amino-2-methylpropanoic acid (1.03 g, 10 mmol) in 2 M NaOH 
(10 mL) was added isocyanatobenzene (2.38 g, 20 mmol) at rt. The mixture was stirred 
at rt overnight. The insoluble diaryl urea side product in the reaction mixture was 
removed by filtration. The filtrate was adjusted to pH=3.0 with 2 M HCl. The resulting 
precipitate was collected by filtration to give 2-methyl-2-(3-phenylureido)propanoic acid 
as a white solid (544 mg, 25%).  
1H NMR (500 MHz, DMSO-d6) δ 1.41 (s, 6H), 6.48 (s, 1H), 6.88 (t, J = 7.3 Hz, 
1H), 7.13 – 7.28 (m, 2H), 7.35 (d, J = 7.4 Hz, 2H), 8.50 (s, 1H). 
13C NMR (126 MHz, DMSO) δ 25.38, 54.75, 117.42, 121.02, 128.63, 140.31, 
154.29, 176.26. 
mp 185–186 oC; (lit. mp 157–158 oC)15(lit. mp 165–166oC)16(lit. mp 117–118 oC)16 
Anal Calcd for C11H14N2O3: C, 59.45; H, 6.35; N, 12.60; Found: C, 59.48; H, 6.42; 
N, 12.80. 
CAS Registry Number 392715-74-1, reported mps are different, commercially 
available 
 
Synthesis of UC03. 
 
To a solution of 4-fluoro-3-(trifluoromethyl)aniline (4.83 g, 27 mmol) in EtOAc (50 
mL) at 0 °C, was added a solution of triphosgene (2.81 g, 9.5 mmol) in toluene (100 mL) 
dropwise. After stirring at 0 oC for 30 min, the reaction mixture was allowed to return to rt 
and then heated at 80 oC overnight. The solvents were evaporated in vacuo to afford 1-
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fluoro-4-isocyanato-2-(trifluoromethyl)benzene as an oil which was used for the next 
step without further purification. 
To a solution of 2-aminoacetic acid (2.25 g, 30 mmol) in 2 M NaOH (50 mL) was 
added 1-fluoro-4-isocyanato-2-(trifluoromethyl)benzene (5.53 g, 27 mmol) in CH3CN (5 
mL). The mixture was stirred at rt overnight. The insoluble diaryl urea side product in the 
reaction mixture was removed by filtration. The filtrate was adjusted to pH=3.0 with 2 M 
HCl. The resulting precipitate was collected by filtration. The crude material was purified 
by silica gel chromatography with successive elution with hexane (100 mL), 
EtOAc/hexane (60 mL / 60 mL), EtOAc (120 mL) and ethanol (200 mL). The crude 
product was further purified by crystallization from a mixture of EtOAc (1 mL) and 
hexane (10 mL) to afford 2-[3-[4-fluoro-3-(trifluoromethyl)phenyl]ureido]acetic acid as a 
white solid (589 mg, 8%).  
1H NMR (500 MHz, DMSO-d6) δ 3.79 (d, J = 5.8 Hz, 2H), 6.50 (t, J = 5.8 Hz, 1H), 
7.38 (t, J = 9.8 Hz, 1H), 7.48 – 7.67 (m, 1H), 7.96 (dd, J = 6.5, 2.8 Hz, 1H), 9.16 (s, 1H), 
12.58 (s, 1H). 
13C NMR (125 MHz, DMSO-d6) δ 41.33, 115.15 (q, J = 5.0 Hz), 116.24 (qd, J = 
32.3, 13.0 Hz), 117.44 (d, J = 21.3 Hz), 122.64 (q, J = 272.2 Hz), 123.34 (d, J = 8.0 Hz), 
137.19, 153.16 (d, J = 246.9 Hz), 155.06, 171.95. 
mp 151–153 oC 
Anal Calcd for C10H8F4N2O3: C, 42.87; H, 2.88; N, 10.00; Found: C, 43.05; H, 
3.00; N, 10.21. 
CAS Registry Number 1282316-91-9, no mp data, commercial available 
 




To a solution of 3-[4-fluoro-3-(trifluoromethyl)phenyl]-5,5-dimethylimidazolidine-
2,4-dione (2.1 g, 7.2mmol) in DMF (30 mL) was added 60% NaH (900 mg, 22mmol) in 
DMF (15 mL) at 0 oC under argon. The mixture was then stirred at rt for 2 h and treated 
dropwise with 1-bromo-3-chloropropane (1695 mg, 10.8 mmol). The mixture was stirred 
at rt for 2 days. The reaction was adjusted to pH=3.0 with acetic acid. After addition of 
H2O (500 mL), the resulting precipitate was collected by filtration and then crystallized 
from CH2Cl2 (2 mL) to afford 2-[3-[4-fluoro-3-(trifluoromethyl)phenyl]-2-
oxotetrahydropyrimidin-1(2H)-yl]-2-methylpropanoic acid as a white solid (1.059 g, 42%).  
mp 234–235 oC 
1H NMR (500 MHz, DMSO-d6) δ 1.36 (s, 6H), 2.04 (p, J = 5.9 Hz, 2H), 3.41 (t, J = 
6.0 Hz, 2H), 3.64 (t, J = 5.7 Hz, 2H), 7.45 (t, J = 9.7 Hz, 1H), 7.52 – 7.61 (m, 1H), 7.64 
(dd, J = 6.6, 2.7 Hz, 1H), 11.83 (s, 1H). 
13C NMR (125 MHz, DMSO-d6) δ 22.46, 23.40, 41.11, 47.38, 60.25, 115.91 (qd, J 
= 32.3, 13.1 Hz), 116.90 (d, J = 21.2 Hz), 122.49 (q, J = 272.0 Hz), 123.68 (q, J = 4.2 
Hz), 130.99 (d, J = 8.7 Hz), 140.75 (d, J = 3.2 Hz), 153.92, 155.18 (d, J = 250.0 Hz), 
175.53. 
Anal Calcd for C15H16F4N2O3: C, 51.73; H, 4.63; N, 8.04; Found: C, 52.00; H, 4.87; 
N, 8.01. 
 





The mixture of 4-fluoro-3-(trifluoromethyl)aniline (537 mg, 3 mmol) and 3,3-
dimethyldihydrofuran-2,5-dione (512 mg, 4 mmol) in THF (10 mL) was stirred at rt 
overnight. The solvent was evaporated in vacuo. The residue was then crystallized from 
CH2Cl2 (10 mL) to afford 4-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-2,2-dimethyl-4-
oxobutanoic acid as a white solid (852 mg, 93%) 
1H NMR (500 MHz, DMSO-d6) δ 1.20 (s, 6H), 2.59 (s, 2H), 7.45 (t, J = 9.8 Hz, 
1H), 7.64 – 7.86 (m, 1H), 8.10 (dd, J = 6.6, 2.6 Hz, 1H), 10.25 (s, 1H), 12.10 (s, 1H). 
13C NMR (125 MHz, DMSO-d6) δ 25.26, 45.57, 116.30 (qd, J = 32.3, 13.3 Hz), 
116.67 (q, J = 4.8 Hz), 117.62 (d, J = 21.4 Hz), 122.51 (q, J = 272.1 Hz), 124.84 (d, J = 
8.1 Hz), 135.91 (d, J = 3.0 Hz), 154.13 (d, J = 248.3 Hz), 169.64, 178.00. 
mp 185–186 oC 




To a solution of 4-methoxy-3,3-dimethyl-4-oxobutanoic acid (320mg, 2.0 mmol) 
and DMF (8 µL) in CH2Cl2 (2 mL) was added SOCl2 (0.3 mL) at rt. The mixture was then 
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stirred at rt overnight. The solvent was removed in vacuo to give methyl 4-chloro-2,2-
dimethyl-4-oxobutanoate, which was used for the next step without further purification. 
To a solution of 4-fluoro-3-(trifluoromethyl)aniline (537 mg, 3 mmol) in DMA (5 
mL) was added methyl 4-chloro-2,2-dimethyl-4-oxobutanoate (356 mg, 2.0 mmol) at rt. 
The mixture was then stirred at rt overnight. After addition of H2O (100 mL), the resulting 
precipitate was filtered and purified by chromatography (sg, CH2Cl2 300 mL) followed by 
crystallization from a mixture of CH2Cl2 (1 mL) and hexane (50 mL) to afford methyl 4-
[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-2,2-dimethyl-4-oxobutanoate as a white solid 
(346 mg, 54%). 
1H NMR (500 MHz, DMSO-d6) δ 1.21 (s, 6H), 2.63 (s, 2H), 3.59 (s, 3H), 7.45 (t, J 
= 9.8 Hz, 1H), 7.65 – 7.84 (m, 1H), 8.06 (dd, J = 6.6, 2.1 Hz, 1H), 10.29 (s, 1H). 
 
To a solution of methyl 4-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-2,2-dimethyl-
4-oxobutanoate (321mg, 1.0mmol) in MeOH (8 mL) was added a solution of NaOH (160 
mg) in H2O (4 mL) at rt. The mixture was then stirred at rt overnight. The reaction was 
adjusted to pH=3.0 with 32% HCl. The solvent was removed in vacuo. After addition of 
H2O (10 mL), the resulting precipitate was filtered and rinsed with H2O (10 mL) to afford 
a mixture of 4-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-2,2-dimethyl-4-oxobutanoic acid 
and 4-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-3,3-dimethyl-4-oxobutanoic acid (1:1) 
as a white solid. 




To a solution of 2-[4-fluoro-3-(trifluoromethyl)phenyl]acetic acid (2.2 g, 10 mmol) 
and DMF (40 µL) in CH2Cl2 (10 mL) was added SOCl2 (1.5 mL) at rt. The mixture was 
then stirred at rt overnight. The solvent was removed in vacuo to give 2-[4-fluoro-3-
(trifluoromethyl)phenyl]acetyl chloride, which was used for the next step without further 
purification. 
To a solution of 2-amino-2-methylpropanoic acid (1030 mg, 10 mmol) in 2 M 
NaOH (10 mL) was added 2-[4-fluoro-3-(trifluoromethyl)phenyl]acetyl chloride (2.4 g, 10 
mmol) in 2 M NaOH (5 mL) at 0 oC dropwise. The mixture was then stirred at 0 oC for 2 h. 
The reaction was adjusted to pH=2 with 32% HCl. The resulting precipitate was filtered 
and crystallized from CH2Cl2 (10 mL) to afford 2-[2-[4-fluoro-3-
(trifluoromethyl)phenyl]acetamido]-2-methylpropanoic acid (1.358 g, 44%) as a white 
solid. 
1H NMR (500 MHz, DMSO-d6) δ 1.34 (s, 6H), 3.52 (s, 2H), 7.44 (dd, J = 10.8, 8.6 
Hz, 1H), 7.51–7.62 (m, 1H), 7.65 (dd, J = 7.2, 2.1 Hz, 1H), 8.37 (s, 1H), 12.18 (s, 1H). 
13C NMR (125 MHz, DMSO-d6) δ 24.86, 40.41, 54.92, 116.08 (qd, J = 32.1, 12.3 
Hz), 116.81 (d, J = 20.4 Hz), 122.70 (q, J = 271.8 Hz), 127.42 (q, J = 4.5 Hz), 133.54 (d, 
J = 3.8 Hz), 135.65 (d, J = 8.5 Hz), 157.58 (dq, J = 251.8, 2.8 Hz), 168.77, 175.33. 
mp 190–191 oC 
 




To a solution of triphosgene (3.680 g, 12.4 mmol) in toluene (100 mL) at 0 °C 
was added a solution of 4-fluoro-3-(trifluoromethyl)aniline (6.300 g, 35.2 mmol) in EtOAc 
(100 mL) dropwise. After stirring at 0 oC for 30 min, the reaction mixture was allowed to 
return to rt and then heated at 70 oC overnight. The solvents were evaporated in vacuo 
to afford 1-fluoro-4-isocyanato-2-(trifluoromethyl)benzene as an oil which was used for 
the next step without further purification. 
To a solution of 1-aminocyclopropanecarboxylic acid (3.066 g, 30.4 mmol) in 1 M 
NaOH (10 mL) was added 1-fluoro-4-isocyanato-2-(trifluoromethyl)benzene (7.216 g, 
35.2 mmol) in CH3CN (10 mL) at 0 oC dropwise. The mixture was stirred at 0 oC for 3 h 
and then was warmed to rt overnight. The reaction mixture was concentrated and then 
redissolved in 1 M NaOH (50 mL). The resulting precipitate, insoluble diaryl urea side 
product, was removed by filtration. The filtrate was adjusted to pH=3.0 with 32% HCl. 
The resulting precipitate was collected by filtration to give 1-[3-[4-fluoro-3-
(trifluoromethyl)phenyl]ureido]cyclopropanecarboxylic acid as a white solid (4274 mg, 
46%).  
1H NMR (500 MHz, DMSO-d6) δ 1.04 (dd, J = 7.7, 4.5 Hz, 2H), 1.35 (dd, J =7.7, 
4.5 Hz, 2H), 7.18 (s, 1H), 7.37 (t, J = 9.8 Hz, 1H), 7.48 – 7.66 (m, 1H), 8.00 (dd, J = 6.5, 
2.7 Hz, 1H), 9.49 (s, 1H), 12.31 (s, 1H). 
13C NMR (125 MHz, DMSO-d6) δ 16.84, 32.97, 114.99, 116.17 (qd, J = 31.9, 12.9 
Hz), 117.37 (d, J = 21.3 Hz), 122.67 (q, J = 272.0 Hz), 123.22 (d, J = 5.9 Hz), 137.33 (d, 
J = 2.7 Hz), 153.06 (d, J = 247.8 Hz), 155.47, 174.46. 
114 
 
mp: 201-202 oC 
Anal Calcd for C12H10F4N2O3·0.7H2O: C, 45.21; H, 3.60; N, 8.79; Found: C, 45.06; 
H, 3.29; N, 8.72. 
Synthesis of UC08. 
 
To a solution of triphosgene (4.144 g, 14 mmol) in toluene (150 mL) at 0 °C was 
added a solution of 4-fluoro-3-(trifluoromethyl)aniline (7.16 g, 40 mmol) in EtOAc (120 
mL) dropwise. After stirring at 0 oC for 30 min, the reaction mixture was allowed to return 
to rt and then heated at 70 oC overnight. The solvents were evaporated in vacuo to 
afford 1-fluoro-4-isocyanato-2-(trifluoromethyl)benzene as an oil which was used for the 
next step without further purification. 
To a solution of 1-aminocyclobutanecarboxylic acid (1.035 g, 9 mmol) in 1 M 
NaOH (15 mL) was added 1-fluoro-4-isocyanato-2-(trifluoromethyl)benzene (2.05 g, 10 
mmol) in CH3CN (10 mL) at 0 oC dropwise. The mixture was stirred at 0 oC for 3 h and 
then was warmed to rt overnight. The reaction mixture was concentrated and the 
resulting precipitate, insoluble diaryl urea side product, was removed by filtration. The 
filtrate was adjusted to pH=3.0 with 32% HCl. The resulting precipitate was collected by 
filtration and then recrystallized from diethyl ether (5 mL) to give 1-[3-[4-fluoro-3-
(trifluoromethyl)phenyl]ureido]cyclobutanecarboxylic acid as a white solid (1.177 g, 41%).  
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1H NMR (500 MHz, DMSO-d6) δ 1.85–2.02 (m, 2H), 2.16 – 2.29 (m, 2H), 2.43–
2.60 (m, 2H), 7.00 (s, 1H), 7.37 (t, J = 9.7 Hz, 1H), 7.44–7.64 (m, 1H), 7.99 (dd, J = 6.6, 
2.7 Hz, 1H), 8.98 (s, 1H), 12.45 (s, 1H). 
13C NMR (125 MHz, DMSO-d6) δ 15.00, 31.00, 57.38, 115.11 (q, J = 5.0 Hz), 
116.28 (qd, J = 32.0, 12.8 Hz), 117.42 (d, J = 21.3 Hz), 122.69 (q, J = 271.9 Hz), 123.36 
(d, J = 7.8 Hz), 137.15 (d, J = 2.6 Hz), 153.19 (dq, J = 247.1, 2.3 Hz), 154.34, 175.20. 
mp: 175-176 oC 
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N,N’-diaryl urea antischistosomal agents 
Abstract 
Novel N,N'-diaryl ureas were designed and synthesized as new analogues of Ro 
13-3978, some of which showed significant antischistosomal effects. The most 
promising compound identified in this work was N,N’-di(quinoxalin-2-yl)urea. This new 
lead compound can serve as a new direction for further optimization. In addition, various 
synthetic routes to diaryl ureas were described. 
5.1. Introduction 
Schistosomiasis is an intravascular disease caused by parasitic trematode 
worms of the genus Schistosoma. The burden of disease attributable to the three major 
human schistosome species (Schistosoma mansoni, S. Haematobium, and S. japonicum) 
is estimated to be almost 200 million infected patients1. More than 90% of the roughly 
200 million cases of schistosomiasis occur in Africa2, 3 and close to 800 million are at risk. 
It is one of the most prevalent of the tropical infectious diseases4. In the absence of 
vaccines5 and with the challenges surrounding implementation of other preventive 
measures such as access to safe water and improved sanitation, the current and 
precarious mainstay for treatment and control of schistosomiasis is praziquantel (PZQ)6, 
7. This dependence on a single drug is alarming, as there is some evidence that 
resistance to PZQ may be emerging in Africa and laboratory studies indicate that 
schistosomes exposed to repeated in vivo PZQ treatments have reduced drug 
sensitivities8, 9.  Furthermore, PZQ is inactive against the juvenile schistosomula; this 
may be an important factor in the frequently observed treatment ‘failures’ in areas 
endemic for schistosomiasis10. Even so, drug discovery for schistosomiasis has 
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languished11-13, although several antischistosomal lead compounds14, 15 have been 
identified in recent years.  
Ingram-Sieber recently screened the MMV malaria box of 400 commercially 
available malaria active compounds for antischistosomal activity16. This library was 
assayed initially against schistosomula and then selected compounds progressed to ex 
vivo and in vivo evaluation against adult schistosomes. The most promising lead 
identified in this work was N,N’-diarylurea MMV665852. It was nearly as potent as 
PZQagainst ex vivo S. mansoni. A single 400 mg/kg oral dose of MMV665852 
administered to S. mansoni-infected mice reduced adult WBR by 53%.16 Previously, we 
had tested the symmetrical N,N’-diarylurea AR33 in S.mansoni-infected mice, as AR33 
was a side product formed in the synthesis of the aryl hydantoins. A single 100 mg/kg 
oral dose of AR33 administered to S. mansoni-infected mice reduced adult WBR by 40% 
indicating that this N,N’-diarylurea is more effective than the lead N,N’-diarylurea 





With the goal of increasing the antischistosomal activity and the solubility of the 
hydrophobic N,N’-diarylurea lead compounds, an initial library of N,N’-diarylureas and 
closely related compounds that could accelerate the SAR for this chemotype and help 
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focus future medicinal chemistry efforts was designed. They include the symmetrical 
diarylureas, unsymmetrical diarylureas and phenylbenzamides.  
Most target compounds maintain the 4-fluoro-3-(trifluoromethyl)phenyl core 
structure of AR33 while involving carboxyl U13 and U16, pyridyl U05, U10 and U11, 
quinoxalinyl U09, isoxazolyl U17, amide U15 and U18, and cyano U14 to increase 
solubility and polarity. AR42 and ARX contain substructure of praziquantel. AR45, AR46 
and AR47 are analogs of anthelmintic niclosamide. U03 and U04 keep the core structure 
of active compound AR43. Symmetrical ureas AR50, U07 and U08 are potential control 
compounds. The final set of target compounds maintain the 4-fluoro-3-
(trifluoromethyl)phenyl substructure with various central urea substructures: 
conformationally-restricted AR41 and size-extension AR39.  
5.3. Chemistry 
Target compounds AR33-U18 were obtained in variable yields by reaction 
between aryl isocyanates ISO-1 or ISO-2 and anilines AR33-1-U18-1 or praziquanamine 
(AR42-1) in different solvents to form the corresponding unsymmetrical urea (scheme 
5.1. and scheme 5.4.)  
Exposure of U07-1 or U08-1 to CDI at rt effected carbonylation to give 
corresponding symmetric ureas U07 or U08 (scheme 5.2.).  
N-arylation via palladium promoted cross-coupling of aryl iodide AR41-1 with 1,3-
ethyleneurea (AR41-2) afforded conformationally restricted diaryl urea AR41. Symmetric 
diaryl ureas U04 and AR50 were obtained in a two-step sequence by reactions between 
pyridylamine U04-1 or aminoquinoxaline AR50-1 and triphosgene to form the 
corresponding isocyanates, which were further reacted with U04-1 or AR50-1 to provide 
U04 and AR50 respectively (Scheme 5.3.).  
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Salicylanilides AR45-AR47 were obtained by the acylation of corresponding 
anilines AR45-1, AR46-1 or AR47-1 with 5-chloro-2-hydroxybenzoyl chloride (BC-1) 
respectively (scheme 5.5.).  
Target compound U03 was synthesized via EDCI-mediated coupling of pyridyl 
carboxylic acid U03-1 with pyridylamine U04-1 in DMA (scheme 5.6.). 
AR39 was obtained in one step by reaction between terephthaloyl chloride 





















(a) Cs2CO3, toluene, Xantphos, pd2(dba)3, DMA, rt, 24 h; 
(b) Triphosgene, DIPEA,CH2Cl2, 0 oC to rt, 12 h; 
(c) DIPEA, CH2Cl2, 2-(trifluoromethyl)pyridin-4-amine,rt, 12 h; 
(d) Triphosgene, toluene, EtOAc, 0 oC-85 oC, 24 h; 
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5.4. Results and Discussion 
This library of urea analogs was assayed initially against NTS and adult worms 
(in vitro) then selected compounds progressed to in vivo evaluation against adult 
schistosomes. The most promising compound identified in this work was AR50. As 
shown in Table 5.1., a single 200 mg/kg oral dose of AR50 administered to S. mansoni-
infected mice reduced adult WBR by 75.1%, while a dose of 100 mg/kg reduced WBR 
by 62%. Thus, this very simple compound offers intriguing possibilities for further 
optimization, although this is tempered by its large PSA of 92.7 Å2. 
Unsymmetrical diaryl ureas, AR38, AR49, U05 and U14, maintain the 4-fluoro-3-
(trifluoromethyl)aniline core of AR33 and involve dichlorophenyl (AR38), cyanophenyl 
(U14), quinoxalinyl (AR49) or pyridyl (U05). These compounds demonstrated in vivo 
activity at 400 mg/kg. 
Salicylanilide compounds were toxic. Two mice, treated with AR46, died 1 and 4 
hours after application. Although the salicylanilides AR45, AR46, and AR47 were active 
in vitro, they were not active in vivo. We suggest that the closely related drug 
niclosamide is not absorbed from the small intestine.  Thus, salicylanilides are not a 
good compound series. 
5.5. Summary 
In conclusion, we designed an initial library of N,N’-diarylureas and closely 
related compounds that could accelerate the SAR for this chemotype and help focus 
future med-chem efforts. The most promising compound identified in this work was N,N’-
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5.6.1. General.   
Melting points are uncorrected. 1D 1H and 13C NMR spectra were recorded on a 500 
MHz spectrometer using CDCl3or DMSO-d6 as solvents. All chemical shifts are reported 
in parts per million (ppm) and are relative to internal (CH3)4Si (0 ppm) for 1H and CDCl3 
(77.2 ppm) or DMSO-d6  (39.5 ppm)for 13C NMR.  EI GC-MS data were obtained using a 
quadrapole mass spectrometer with 30 m DB-XLB type columns and a He flow rate of 1 
mL/min.  Silica gel (sg) particle size 32−63 μm was used for all flash column 
chromatography.  Reported reaction temperatures are those of the oil bath.   
5.6.2. Synthesis 
1. Synthesis of AR33. 
 
A mixture of 4-fluoro-3-(trifluoromethyl)aniline (1.79 g, 10 mmol) and 1-fluoro-4-
isocyanato-2-(trifluoromethyl)benzene (2.05 g, 10 mmol) in CH3CN (10 mL) was stirred 
at rt overnight. Evaporation gave a crude product which was further purified by 
successive recrystallizations from H2O (20 mL) and a mixture of EtOAc (3 mL) and 
hexane (5 mL) to afford 1,3-bis[4-fluoro-3-(trifluoromethyl)phenyl]urea (1.501 g, 39%) as 
a white solid. 
mp: 198-199 oC 
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1H NMR (500 MHz, DMSO-d6) δ 7.45 (t, J = 9.8 Hz, 2H), 7.60–7.75 (m, 2H), 7.98 (dd, J 
= 6.7, 2.6 Hz, 2H), 9.17 (s, 2H). 
13C NMR (126 MHz, DMSO-d6) δ 116.38 (q, J = 5.0 Hz), 116.67 (qd, J = 32.1, 12.9 Hz), 
117.33 (d, J = 21.7 Hz), 122.70 (q, J = 271.9 Hz), 124.36 (d, J = 8.1 Hz), 136.34 (d, J = 
2.7 Hz), 152.69, 153.97 (d, J = 248.7 Hz). 
Anal Calcd for C15H8F8N2O: C, 46.89; H, 2.10; N, 7.29; Found: C, 47.00; H, 2.37; N, 7.34 
CAS Registry Number 35685-20-2, No mp data. 
2. Synthesis of AR38. 
 
To a solution of 1,2-dichloro-4-isocyanatobenzene (1.710 g, 9.1 mmol) in CH2Cl2 (100 
mL) was added 4-fluoro-3-(trifluoromethyl)aniline (2.443 g, 13.6 mmol). The reaction 
mixture was stirred at rt for 20 h. The precipitation was collected by filtration and washed 
with CH2Cl2 (10 mL) to afford 1-(3,4-dichlorophenyl)-3-[4-fluoro-3-
(trifluoromethyl)phenyl]urea as (3.000 g, 90%) a white solid. 
mp 234–235 oC 
1H NMR (500 MHz, DMSO-d6) δ 7.37 (dd, J = 8.8, 2.5 Hz, 1H), 7.44 (t, J = 9.8 Hz, 1H), 
7.52 (d, J = 8.8 Hz, 1H), 7.60–7.71 (m, 1H), 7.88 (d, J = 2.4 Hz, 1H), 7.99 (dd, J = 6.6, 
2.6 Hz, 1H), 9.12 (s, 1H), 9.16 (s, 1H). 
133 
 
13C NMR (125 MHz, DMSO-d6) δ 116.36 (d, J = 5.2 Hz), 116.39 (qd, J = 32.2, 13.1 Hz), 
117.57 (d, J = 21.4 Hz), 118.64, 119.63, 122.57 (q, J = 271.9 Hz), 123.49, 124.59 (d, J = 
8.0 Hz), 130.53, 131.03, 136.17 (d, J = 2.7 Hz), 139.63, 152.38, 153.82 (d, J = 248.0 Hz). 
Anal Calcd for C14H8Cl2F4N2O: C, 45.80; H, 2.20; N, 7.63; Found: C, 46.12; H, 2.21; N, 
7.89. 
CAS Registry Number 799-22-4, no mp data, commercial available 
 
3. Synthesis of AR39. 
 
To a solution of 4-fluoro-3-(trifluoromethyl)aniline (3.943 g, 22 mmol) and TEA (4.100 g, 
40 mmol) in DMA (40 mL) was added terephthaloyl dichloride (2.020 g, 10 mmol) at rt. 
After it was stirred at rt for 24 h, the reaction mixture was poured into water (200 mL). 
The precipitation was collected by filtration and washed with CHCl3 (10 mL) to afford 
N1,N4-bis[4-fluoro-3-(trifluoromethyl)phenyl]terephthalamide (4.293 g, 88%) as a white 
solid. 
mp 305–306 oC 
1H NMR (500 MHz, DMSO-d6) δ 7.56 (t, J = 9.8 Hz, 2H), 8.06–8.18 (m, 6H), 8.28 (dd, J 
= 6.6, 2.8 Hz, 2H), 10.73 (s, 2H). 
13C NMR (125 MHz, DMSO-d6) δ 116.45 (qd, J = 32.4, 13.1 Hz), 117.51 (d, J = 21.5 Hz), 
118.52 (d, J = 5.2 Hz), 122.56 (q, J = 271.8 Hz), 126.43 (d, J = 8.3 Hz), 127.80, 135.77 
(d, J = 3.0 Hz), 137.11, 154.78 (d, J = 250.5 Hz), 164.99. 
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Anal Calcd for C22H12F8N2O2·1.5 H2O: C, 51.27; H, 2.93; N, 5.44; Found: C, 51.66; H, 
3.21; N, 5.00. 
4. Synthesis of AR41. 
 
To a solution of 1-fluoro-4-iodo-2-(trifluoromethyl)benzene (1500 mg, 5.2 mmol), 
imidazolidin-2-one (344 mg, 4 mmol) and Cs2CO3 (2.700 g, 8.3 mmol) in toluene (46 mL) 
were added xantphos (120 mg, 0.2 mmol) and pd2(dba)3 (93 mg, 0.1 mmol). After it was 
heated at 80oC under argon overnight, the solvent was evaporated in vacuo. The residue 
was purified by chromatography (EtOAc:hexane 1:1) to afford 1,3-bis[4-fluoro-3-
(trifluoromethyl)phenyl]imidazolidin-2-one (345 mg, 21%) as a white solid. 
mp 153–154 oC 
1H NMR (500 MHz, DMSO-d6) δ 4.05 (s, 4H), 7.56 (t, J = 9.8 Hz, 2H), 7.77–7.91 (m, 2H), 
8.14 (dd, J = 6.5, 2.8 Hz, 2H). 
13C NMR (126 MHz, DMSO-d6) δ 41.45, 115.92 (q, J = 4.9 Hz), 116.45 (qd, J = 32.2, 
13.1 Hz), 117.61 (d, J = 21.4 Hz), 122.70 (q, J = 272.1 Hz), 123.85 (d, J = 8.0 Hz), 
136.56 (d, J = 2.7 Hz), 154.11 (dq, J = 249.3, 2.2 Hz), 154.34. 
GC-MS purity: 100% 





5. Synthesis of AR42. 
 
The mixture of 1,2,3,6,7,11b-hexahydro-4H-Pyrazino[2,1-a]isoquinolin-4-one(737 mg, 
3.64 mmol) and 1-fluoro-4-isocyanato-2-(trifluoromethyl)benzene (498 mg, 2.43 mmol) in 
CH2Cl2 (24 mL) was stirred at rt overnight. The precipitation was collected by filtration 
and washed with CH2Cl2 (1 mL) to afford N-[4-fluoro-3-(trifluoromethyl)phenyl]-4-oxo-
3,4,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinoline-2(11bH)-carboxamide (459 mg, 46%) 
as a white solid. 
mp 227–228 oC 
1H NMR (500 MHz, DMSO-d6) δ 2.74–2.95 (m, 3H), 3.14 (dd, J = 13.2, 10.6 Hz, 1H), 
3.96 (d, J = 17.3 Hz, 1H), 4.44 (d, J = 17.3 Hz, 1H), 4.57 (dt, J = 11.4, 3.6 Hz, 1H), 4.62–
4.72 (m, 1H), 4.97 (dd, J = 10.6, 4.2 Hz, 1H), 7.20–7.34 (m, 3H), 7.38–7.47 (m, 2H), 7.83 
(dt, J = 7.9, 3.7 Hz, 1H), 7.97 (dd, J = 6.5, 2.7 Hz, 1H), 9.05 (s, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 28.23, 38.24, 46.91, 47.54, 54.23, 116.09 (qd, J = 32.0, 
12.8 Hz), 117.25 (d, J = 21.1 Hz), 117.55 (d, J = 5.4 Hz), 122.69 (q, J = 272.3 Hz), 
125.53 (d, J = 7.9 Hz), 125.65, 126.58, 127.09, 129.08, 133.40, 135.10, 136.98 (d, J = 
2.8 Hz), 153.82 (d, J = 248.3 Hz), 154.03, 164.52. 




6. Synthesis of AR45. 
 
To a solution of 5-chloro-2-hydroxybenzoic acid (1.7 g, 9.9 mmol) in toluene (5 mL) was 
added thionyl chloride (5 mL).The reaction mixture was heated to 70 oC overnight.  
The solvent was then evaporated in vacuo to afford 5-chloro-2-hydroxybenzoyl chloride 
which was used for the next step without further purification.  
To a solution of 5-chloro-2-hydroxybenzoyl chloride in CH2Cl2 (10 mL) was added a 
mixture of 4-fluoro-3-(trifluoromethyl)aniline (1.180 g, 6.6 mmol), DMAP (85.4 mg, 0.7 
mmol) and Et3N (1.3 g, 13 mmol). After stirring at rt overnight, the solvent was 
evaporated in vacuo. The residue was purified by successive crystallization from a 
mixture of CH3CN (3 mL) and H2O (30 mL) and a mixture of DMSO (2 mL) and H2O (20 
mL) to afford 5-chloro-N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-hydroxybenzamide (0.569 
g, 24%) as a white solid. 
mp 197–198 oC (lit. mp 203–205 oC)17 
1H NMR (500 MHz, DMSO-d6) δ 7.03 (d, J = 8.8 Hz, 1H), 7.48 (dd, J = 8.9, 2.7 Hz, 1H), 
7.55 (t, J = 9.8 Hz, 1H), 7.88 (d, J = 2.7 Hz, 1H), 7.96–8.13 (m, 1H), 8.22 (dd, J = 6.7, 
2.6 Hz, 1H), 10.65 (s, 1H), 11.56 (s, 1H). 
13C NMR (125 MHz, DMSO-d6) δ 116.43 (qd, J = 32.1, 13.0 Hz), 117.65 (d, J = 21.4 Hz), 
118.75 (d, J = 5.0 Hz), 119.08, 119.78, 122.48 (q, J = 271.9 Hz), 122.62, 126.82 (d, J = 
8.3 Hz), 128.39, 133.10, 134.97 (d, J = 3.0 Hz), 154.92 (d, J = 250.6 Hz), 156.68, 165.21. 
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Anal Calcd for C14H8ClF4NO2: C, 50.40; H, 2.42; N, 4.20; Found: C, 50.50; H, 2.68; N, 
4.30. 
 
7. Synthesis of AR46. 
 
A solution of 5-chloro-2-hydroxybenzoic acid (1.7 g, 10 mmol) and SOCl2 (5 mL) in 
toluene (5 mL) was stirred at 70 oC overnight. The mixture was concentrated to afford 
the 5-chloro-2-hydroxybenzoyl chloride which was used for the next step without further 
purification. To a solution of 3,5-bis(trifluoromethyl)aniline (1.526 g, 6.6 mmol) in CH2Cl2 
(10 mL) were added the acid chloride, Et3N (1.3 g, 13 mmol), and DMAP (85.4 mg, 0.7 
mmol). The mixture was stirred at room temperature overnight. After removal of CH2Cl2 
under reduced pressure, the residue was recrystallized from a mixture of CH3CN (4 mL) 
and H2O (30 mL) to afford N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-
hydroxybenzamide (0.73 g, 29%) as a white solid.  
mp 175–177 oC; (lit. mp 172–173 oC)17 
1H NMR (500 MHz, DMSO-d6) δ 7.04 (d, J = 8.8 Hz, 1H), 7.49 (dd, J = 8.8, 2.7 Hz, 1H), 
7.85 (s, 1H), 7.86 (d, J = 2.7 Hz, 1H), 8.45 (s, 2H), 10.94 (s, 1H), 11.40 (s, 1H). 
13C NMR (125 MHz, DMSO-d6) δ 116.79, 119.15, 120.15, 120.26, 122.45, 123.21 (q, J = 
272.9 Hz), 128.55, 130.70 (q, J = 32.9 Hz), 133.18, 140.31, 156.66, 165.51. 
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Anal Calcd for C15H8ClF6NO2: C, 46.96; H, 2.10; N, 3.65; Found: C, 47.12; H, 2.21; N, 
3.85. 
 
8. Synthesis of AR47. 
 
To a solution of 5-chloro-2-hydroxybenzoic acid (3.5 g, 20.3 mmol) in toluene (10 mL) 
was added thionyl chloride (10 mL).The reaction mixture was heated to 70 oC overnight.  
The solvent was then evaporated in vacuo to afford 5-chloro-2-hydroxybenzoyl chloride 
which was used for the next step without further purification.  
To a solution of 5-chloro-2-hydroxybenzoyl chloride in CH2Cl2 (50 mL) was added a 
mixture of 3,4-dichloroaniline (2.1 g, 12.9 mmol), DMAP (175 mg, 1.5 mmol) and Et3N 
(2.6 g, 26 mmol). After stirring at rt overnight, the solvent was evaporated in vacuo. The 
residue was purified by crystallization from a mixture of acetic acid (1 mL), CH3CN (1 mL) 
and H2O (10 mL), and then successive recrystallization from a mixture of xylene (1 mL) 
and hexane (10 mL) and a mixture of DMSO (2 mL) and H2O (20 mL) to afford 5-chloro-
N-(3,4-dichlorophenyl)-2-hydroxybenzamide (1.574 g, 39%) as a white solid. 
mp 243–245 oC; (lit. mp 246–248 oC)18 
1H NMR (500 MHz, DMSO-d6) δ 7.03 (d, J = 8.8 Hz, 1H), 7.47 (dd, J = 8.8, 2.7 Hz, 1H), 
7.62 (d, J = 8.8 Hz, 1H), 7.68 (dd, J = 8.8, 2.4 Hz, 1H), 7.87 (d, J = 2.7 Hz, 1H), 8.11 (d, 
J = 2.3 Hz, 1H), 10.56 (s, 1H), 11.56 (s, 1H). 
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13C NMR (125 MHz, DMSO-d6) δ 119.00, 120.09, 120.57, 121.76, 122.73, 125.65, 
128.49, 130.63, 130.97, 133.05, 138.31, 156.32, 164.98. 
Anal Calcd for C13H8Cl3NO2: C, 49.32; H, 2.55; N, 4.42; Found: C, 49.41; H, 2.68; N, 
4.53 
9. Synthesis of AR49. 
 
To a solution of triphosgene (1 g, 3.4 mmol) in toluene (40 mL) at 0 oC was added a 
solution of 4-fluoro-3-(trifluoromethyl)aniline (1.79 g, 10 mmol) in CH2Cl2 (20 mL) 
dropwise. After stirring at 0 oC for 30 min, the reaction mixture was allowed to return to rt 
and then heated at 80 oC overnight. The solvents were evaporated in vacuo to afford 1-
fluoro-4-isocyanato-2-(trifluoromethyl)benzene as an oil which was used for the next 
step without further purification. 
A mixture of quinoxalin-2-amine (0.5 g, 3.4 mmol) and 1-fluoro-4-isocyanato-2-
(trifluoromethyl)benzene (2.05 g, 10 mmol) in CH3CN (20 mL) was refluxed overnight. 
After cooling to rt, the resulting precipitate was filtered and crystallized from hot 
methanol to afford 1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(quinoxalin-2-yl)urea (0.743 g, 
61%) as a white solid. 
1H NMR (500 MHz, DMSO-d6) δ 7.52 (t, J = 9.7 Hz, 1H), 7.68 (ddd, J = 8.3, 7.0, 1.4 Hz, 
1H), 7.81 (ddd, J = 8.3, 7.0, 1.5 Hz, 1H), 7.88 (dt, J = 8.0, 3.5 Hz, 1H), 8.03 (ddd, J = 




13C NMR (125 MHz, DMSO-d6) δ 116.52 (qd, J = 32.2, 13.0 Hz), 117.18 (q, J = 5.5 Hz), 
117.72 (d, J = 21.5 Hz), 122.53 (q, J = 272.3 Hz), 125.68 (d, J = 8.2 Hz), 126.92, 127.30, 
128.63, 130.67, 135.28, 138.21, 138.67, 139.50, 147.24, 152.02, 154.39 (d, J = 249.3 
Hz). 
mp: 270-272 oC 
Anal Calcd for C16H10F4N4O: C, 54.86; H, 2.88; N, 16.00; Found: C, 55.00; H, 3.00; N, 
16.22 
 
10. Synthesis of AR50. 
 
To a solution of triphosgene (360 mg, 1.22 mmol) in toluene (30 mL) at 0 oC was added 
a solution of quinoxalin-2-amine (530 mg, 3.65 mmol) in EtOAc (30 mL) dropwise. After 
stirring at 0 oC for 30 min, the reaction mixture was allowed to return to rt and then 
heated at 80 oC for 24 h. The solvents were evaporated in vacuo to afford 2-
isocyanatoquinoxaline which was used for the next step without further purification. 
To a solution of 2-amino-2-methylpropanoic acid (134 mg, 1.3 mmol) in 2 M NaOH (5 mL) 
was added 2-isocyanatoquinoxaline (625 mg, 3.65 mmol). The reaction mixture was 
stirred at rt overnight. The precipitated byproduct was filtered to afford 1,3-di(quinoxalin-
2-yl)urea (307 mg, 53%) as a white solid. 
mp: 303-305 oC 
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1H NMR (500 MHz, DMSO-d6) δ 7.73 (ddd, J = 8.3, 6.9, 1.4 Hz, 2H), 7.85 (ddd, J = 8.4, 
6.9, 1.4 Hz, 2H), 7.94 (d, J = 8.3 Hz, 2H), 8.06 (d, J = 8.3 Hz, 2H), 9.41 (s, 2H), 11.26 (s, 
2H). 
13C NMR (125 MHz, DMSO) δ 126.95, 127.81, 128.78, 130.89, 138.90, 139.43, 147.03, 
151.68. 
Anal Calcd for C17H12N6O: C, 64.55; H, 3.82; N, 26.57; Found: C, 64.81; H, 4.00; N, 
26.56. 
11. Synthesis of U03. 
 
To a solution of 2-(trifluoromethyl)pyridin-4-amine(162 mg, 1 mmol) and 2-
(trifluoromethyl)isonicotinic acid (172 mg, 0.9 mmol)  in DMA (4 mL) was added1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (200 mg, 1 mmol) at rt. The 
mixture was then stirred at rt overnight. After addition of H2O (75 mL), the resulting 
precipitate was filtered to afford 2-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-
yl]isonicotinamide (138 mg, 46%) as a white solid. 
1H NMR (500 MHz, DMSO-d6) δ 8.04 (dd, J = 5.8, 1.9 Hz, 1H), 8.22 (dd, J = 4.9, 1.6 Hz, 
1H), 8.27 (d, J = 2.0 Hz, 1H), 8.39 (d, J = 1.1 Hz, 1H), 8.73 (d, J = 5.5 Hz, 1H), 9.04 (d, J 
= 5.0 Hz, 1H), 11.31 (s, 1H). 
13C NMR (125 MHz, DMSO-d6) δ 110.98 (q, J = 3.2 Hz), 116.83, 118.73 (q, J = 2.8 Hz), 
121.43 (q, J = 274.5), 121.58 (q, J = 274.8), 125.62, 143.09, 146.70–147.78 (m), 147.13, 
151.36, 151.37, 164.03. 
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mp 108–110 oC 
Anal Calcd for C13H7F6N3O·0.5H2O: C, 45.36; H, 2.34; N, 12.21; Found: C, 45.81; H, 
2.60; N, 11.83. 
 
12. Synthesis of U04. 
 
To a mixture of 2-(trifluoromethyl)pyridin-4-amine (314 mg, 1.9 mmol) and N,N-
diisopropylethylamine (774 mg, 6 mmol) in CH2Cl2 (30 mL) at 0 oC was added a solution 
of triphosgene (592 mg, 2 mmol) in CH2Cl2 (20 mL) dropwise. The reaction mixture was 
allowed to return to rt overnight. The solvents were evaporated in vacuo to afford 4-
isocyanato-2-(trifluoromethyl)pyridine which was used for the next step without further 
purification. 
To a solution of 4-isocyanato-2-(trifluoromethyl)pyridine (357 mg, 1.9 mmol) and N,N-
diisopropylethylamine (238 mg, 1.8 mmol) in CH2Cl2 (10 mL) was added 2-
(trifluoromethyl)pyridin-4-amine (300 mg, 1.8 mmol) at rt. After the mixture was stirred at 
rt overnight, and additional portion of triphosgene (416mg, 1.4 mmol) and N,N-
diisopropylethylamine (548 mg, 4.2 mmol) was added. The mixture was then stirred at rt 
overnight. The solvent was evaporated in vacuo. The residue was then crystallized from 
ethanol:H2O (1:3) to afford 1,3-bis[2-(trifluoromethyl)pyridin-4-yl]urea (236 mg, 37%) as a 
white to pale yellow solid. 
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1H NMR (500 MHz, DMSO-d6) δ 7.66 (d, J = 4.7 Hz, 2H), 8.07 (s, 2H), 8.59 (d, J = 5.6 
Hz, 2H), 9.92 (s, 2H). 
13C NMR (125 MHz, DMSO-d6) δ 109.32, 115.39, 121.61 (q, J = 274.2 Hz), 147.33 (q, J 
= 33.2 Hz), 147.64, 150.91, 151.82. 
mp 205–207 oC 
Anal Calcd for C13H8F6N4O·0.3H2O: C, 43.91; H, 2.44; N, 15.75; Found: C, 44.19; H, 
2.71; N, 15.33.  
 
13. Synthesis of U05. 
To a solution of triphosgene (658 mg, 2.2 mmol) in toluene (8 mL) at 0 oC was added a 
solution of 4-fluoro-3-(trifluoromethyl)aniline (1.199 g, 6.7 mmol) in EtOAc (6 mL) 
dropwise. After stirring at 0 oC for 30 min, the reaction mixture was allowed to return to rt 
and then heated at 80 oC overnight. The solvents were evaporated in vacuo to afford 1-
fluoro-4-isocyanato-2-(trifluoromethyl)benzene as an oil which was used for the next 
step without further purification. 
To a solution of pyridin-2-amine (622 mg, 6.6 mmol) in THF (19 mL) was added 1-fluoro-
4-isocyanato-2-(trifluoromethyl)benzene (1.37 g, 6.7 mmol) in THF (7 mL) at rt. The 
reaction mixture was stirred at 80 °C for 4 h. The solvent was evaporated in vacuo. The 
residue was then crystallized from EtOAc to afford1-[4-fluoro-3-(trifluoromethyl)phenyl]-
3-(pyridin-2-yl)urea (430 mg, 22%) as a white solid. 
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1H NMR (500 MHz, DMSO-d6) δ 6.94–7.11 (m, 1H), 7.39–7.54 (m, 2H), 7.69–7.82 (m, 
2H), 8.08 (dd, J = 6.6, 2.7 Hz, 1H), 8.30 (d, J = 5.2 Hz, 1H), 9.57 (s, 1H), 10.87 (s, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 112.01, 116.34 (d, J = 13.0 Hz), 116.63 (q, J = 5.2 Hz), 
117.59, 117.74, 122.57 (q, J = 271.4 Hz), 124.98 (d, J = 8.0 Hz), 135.87, 138.65, 146.91, 
152.30, 152.57, 153.98 (d, J = 249.5 Hz). 
mp: 223 oC 
Anal Calcd for C13H9F4N3O: C, 52.18; H, 3.03; N, 14.04; Found: C, 52.40; H, 3.16; N, 
13.89. 
 
14. Synthesis of U07. 
 
A mixture of pyridin-4-amine (1.91 g, 20 mmol) and 1,1'-Carbonyldiimidazole (CDI) (1.09 
g, 6.7 mmol) in THF (25 mL) was stirred at rt for 48 h. The solvent was evaporated in 
vacuo. The residue was crystallized from H2O (20 mL) and dried to afford1,3-di(pyridin-
4-yl)urea (1.207 g, 84%) as a white solid. 
1H NMR (500 MHz, DMSO-d6) δ 7.45 (d, J = 6.5 Hz, 4H), 8.39 (d, J = 6.4 Hz, 4H), 9.30 
(s, 2H). 
13C NMR (126 MHz, DMSO-d6) δ 112.53, 145.98, 150.26, 151.80. 
mp: 187-189 oC; (lit. mp 218–220 oC)19; (lit. mp 202–203 oC)20 
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Anal Calcd for C11H10N4O·0.4H2O: C, 59.67; H, 4.92; N, 25.30; Found: C, 59.53; H, 4.55; 
N, 25.45. 
 
15. Synthesis of U08. 
 
A mixture of pyrazin-2-amine (1.045 g, 11 mmol) and 1,1'-Carbonyldiimidazole (CDI) 
(810 mg, 5 mmol) in THF (19 mL) was stirred at rt 48 h. The precipitation was collected 
by filtration according to the method of Gube et al. (2012). The crude was crystallized 
from H2O (10 mL) to afford 1,3-di(pyrazin-2-yl)urea (185 mg, 17%) as a pale yellow solid. 
1H NMR (500 MHz, DMSO-d6) δ 8.34 (d, J = 2.6 Hz, 2H), 8.37 (dd, J = 2.6, 1.5 Hz, 2H), 
9.14 (d, J = 1.5 Hz, 2H), 10.27 (s, 2H). 
13C NMR (125 MHz, DMSO) δ 135.42, 138.82, 142.00, 148.67, 151.17. 
mp: 288-290 oC; (lit. mp 197 oC)21 
Anal Calcd for C9H8N6O: C, 50.00; H, 3.73; N, 38.87; Found: C, 50.09; H, 3.80; N, 38.63. 
 
16. Synthesis of U09. 
To a solution of triphosgene (2.26 g, 7.6 mmol) in toluene (32 mL) at 0 oC was added a 
solution of 4-fluoro-3-(trifluoromethyl)aniline (3.43 g, 19.2 mmol) in EtOAc (20 mL) 
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dropwise. After stirring at 0 oC for 30 min, the reaction mixture was allowed to return to rt 
and then heated at 80 oC overnight. The solvents were evaporated in vacuo to afford 1-
fluoro-4-isocyanato-2-(trifluoromethyl)benzene as an oil which was used for the next 
step without further purification. 
To a solution of pyrazin-2-amine (1.8 g, 18.9 mmol) in THF (50 mL) was added 1-fluoro-
4-isocyanato-2-(trifluoromethyl)benzene (3.936 g, 19.2 mmol) in THF (20 mL) at rt. The 
reaction mixture was heated under reflux for 12 h. The solvent was evaporated in vacuo. 
The residue was then crystallized from a mixture of CH2Cl2 (1 mL) and hexane (5 mL) 
and then recrystallized from diethyl ether (2 mL) to afford1-[4-fluoro-3-
(trifluoromethyl)phenyl]-3-(pyrazin-2-yl)urea (0.596 g, 11%) as a pale yellow solid. 
1H NMR (500 MHz, DMSO-d6) δ 7.49 (t, J = 9.7 Hz, 1H), 7.67–7.79 (m, 1H), 8.04 (dd, J 
= 6.5, 2.8 Hz, 1H), 8.29 (d, J = 2.7 Hz, 1H), 8.34 (dd, J = 2.7, 1.5 Hz, 1H), 9.02 (d, J = 
1.5 Hz, 1H), 9.71 (s, 1H), 9.96 (s, 1H). 
13C NMR (125 MHz, DMSO-d6) δ 116.51 (qd, J = 32.3, 13.2 Hz), 116.72 (q, J = 4.1 Hz), 
117.74 (d, J = 21.5 Hz), 122.53 (q, J = 273.5 Hz), 125.05 (d, J = 8.2 Hz), 135.28, 135.57 
(d, J = 2.9 Hz), 138.11, 141.66, 149.05, 151.85, 154.13 (dq, J = 248.9, 2.3 Hz). 
mp: 220-222 oC 







17. Synthesis of U10. 
 
To a solution of triphosgene (855 mg, 2.9 mmol) in toluene (10.5 mL) at 0 oC was added 
a solution of 4-fluoro-3-(trifluoromethyl)aniline (1.566 g, 8.7 mmol) in EtOAc (8 mL) 
dropwise. After stirring at 0 oC for 30 min, the reaction mixture was allowed to return to rt 
and then heated at 80 oC overnight. The solvents were evaporated in vacuo to afford 1-
fluoro-4-isocyanato-2-(trifluoromethyl)benzene as an oil which was used for the next 
step without further purification. 
To a solution of pyridin-3-amine (813 mg, 8.6 mmol) in THF (26 mL) was added 1-fluoro-
4-isocyanato-2-(trifluoromethyl)benzene (1.775 g, 8.7 mmol) in THF (9 mL) at rt. The 
reaction mixture was stirred at 80 °C for 4 h. The solvent was evaporated in vacuo. The 
residue was then crystallized from EtOAc to afford1-[4-fluoro-3-(trifluoromethyl)phenyl]-
3-(pyridin-3-yl)urea (350 mg, 14%) as a white solid.  
1H NMR (500 MHz, DMSO-d6) δ 7.47 (t, J = 9.8 Hz, 1H), 7.61 (dd, J = 8.5, 5.0 Hz, 1H), 
7.68 (dt, J = 9.1, 3.7 Hz, 1H), 8.00 (dd, J = 6.4, 2.8 Hz, 1H), 8.14 (d, J = 8.7 Hz, 1H), 
8.35 (d, J = 5.0 Hz, 1H), 8.84 (s, 1H), 9.51 (s, 1H), 9.52 (s, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 116.18 (q, J = 4.3 Hz), 116.46 (qd, J = 32.2, 13.1 Hz), 
117.72 (d, J = 21.5 Hz), 122.56 (q, J = 272.0 Hz), 124.48 (d, J = 8.0 Hz), 125.47, 129.48, 
135.64, 136.07 (d, J = 2.8 Hz), 137.69, 139.10, 152.52, 153.88 (dq, J = 248.4, 2.0 Hz). 
mp: 233-235 oC 
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Anal Calcd for C13H9F4N3O: C, 52.18; H, 3.03; N, 14.04; Found: C, 52.08; H, 3.20; N, 
14.08. 
 
18. Synthesis of U11. 
 
To a solution of triphosgene (721 mg, 2.4 mmol) in toluene (10 mL) at 0 oC was added a 
solution of 4-fluoro-3-(trifluoromethyl)aniline (1305 mg, 7.3 mmol) in EtOAc (7 mL) 
dropwise. After stirring at 0 oC for 30 min, the reaction mixture was allowed to return to rt 
and then heated at 80 oC overnight. The solvents were evaporated in vacuo to afford 1-
fluoro-4-isocyanato-2-(trifluoromethyl)benzene as an oil which was used for the next 
step without further purification. 
To a solution of pyridin-4-amine (686 mg, 7.3 mmol) in THF (22 mL) was added 1-fluoro-
4-isocyanato-2-(trifluoromethyl)benzene (1496 mg, 7.3 mmol) in THF (7 mL) at rt. The 
reaction mixture was stirred at 80 °C for 4 h. The solvent was evaporated in vacuo. The 
residue was then successively crystallized from EtOAc and diethyl ether to afford1-[4-
fluoro-3-(trifluoromethyl)phenyl]-3-(pyridin-4-yl)urea (235 mg, 11%) as a white solid.  
1H NMR (500 MHz, DMSO-d6) δ 7.40–7.52 (m, 3H), 7.67 (dt, J = 7.7, 3.6 Hz, 1H), 7.99 
(dd, J = 6.5, 2.8 Hz, 1H), 8.38 (d, J = 6.4 Hz, 2H), 9.26 (s, 1H), 9.32 (s, 1H). 
13C NMR (125 MHz, DMSO-d6) δ 112.50, 116.43 (q, J = 5.2 Hz), 117.68 (d, J = 21.5 Hz), 
122.54 (q, J = 272.1 Hz), 124.75 (d, J = 8.4 Hz), 135.95 (d, J = 2.8 Hz), 146.49, 149.86, 
152.19, 153.94 (d, J = 249.1 Hz). 
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mp: 185 oC 
Anal Calcd for C13H9F4N3O: C, 52.18; H, 3.03; N, 14.04; Found: C, 52.40; H, 3.00; N, 
14.02. 
 
19. Synthesis of U13. 
 
To a solution of triphosgene (1.12 g, 3.8 mmol) in toluene (32 mL) at 0 oC, was added a 
solution of 4-fluoro-3-(trifluoromethyl)aniline (1.79 g, 10 mmol) in EtOAc (16 mL) 
dropwise. After stirring at 0 oC for 30 min, the reaction mixture was allowed to return to rt 
and then heated at 80 oC overnight. The solvents were evaporated in vacuo to afford 1-
fluoro-4-isocyanato-2-(trifluoromethyl)benzene as an oil which was used for the next 
step without further purification. 
A mixture of 3-aminobenzoic acid (2.74 g, 20 mmol) and 1-fluoro-4-isocyanato-2-
(trifluoromethyl)benzene (2.05 g, 10 mmol) in CH3CN (40 mL) was stirred at 80 oC for 22 
h. After addition of 2 M HCl (200 mL) and heated at 80 oC for 10 min, the resulting 
precipitate was filtered and crystallized from H2O (50 mL) and then diethyl ether (10 mL) 




1H NMR (500 MHz, DMSO-d6) δ 7.42 (t, J = 7.8 Hz, 1H), 7.45 (t, J = 9.9 Hz, 1H), 7.58 (d, 
J = 7.7 Hz, 1H), 7.62–7.74 (m, 2H), 8.02 (dd, J = 6.5, 2.7 Hz, 1H), 8.15 (s, 1H), 9.03 (s, 
1H), 9.06 (s, 1H), 12.94 (s, 1H). 
13C NMR (125 MHz, DMSO-d6) δ 116.15 (q, J = 4.2 Hz), 116.37 (qd, J = 32.1, 13.0 Hz), 
117.56 (d, J = 21.5 Hz), 119.23, 122.61 (q, J = 272.1 Hz), 122.74, 123.01, 124.42 (d, J = 
8.1 Hz), 128.98, 131.35, 136.45 (d, J = 2.7 Hz), 139.64, 152.59, 153.68 (dq, J = 248.1, 
2.2 Hz), 167.23. 
mp: 317-320 oC 
Anal Calcd for C15H10F4N2O3: C, 52.64; H, 2.95; N, 8.19; Found: C, 52.48; H, 3.11; N, 
8.21. 
 
20. Synthesis of U14. 
 
To a solution of triphosgene (3.41 g, 11.5 mmol) in toluene (90 mL) at 0 oC, was added a 
solution of 4-fluoro-3-(trifluoromethyl)aniline (5.90 g, 33.0 mmol) in EtOAc (50 mL) 
dropwise. After stirring at 0 oC for 30 min, the reaction mixture was allowed to return to rt 
and then heated at 80 oC overnight. The solvents were evaporated in vacuo to afford 1-
fluoro-4-isocyanato-2-(trifluoromethyl)benzene as an oil which was used for the next 
step without further purification. 
A mixture of 4-aminobenzonitrile (1.888 g, 16 mmol) and 1-fluoro-4-isocyanato-2-
(trifluoromethyl)benzene (1.69 g, 8.25 mmol) in CH3CN (13.75 mL) was stirred at 80 oC 
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overnight. After addition of 2 M HCl (50 mL), the resulting precipitate was filtered and 
crystallized from diethyl ether (10 mL) to afford 1-(4-cyanophenyl)-3-[4-fluoro-3-
(trifluoromethyl)phenyl]urea (1.443 g, 54%) as a white solid. 
1H NMR (500 MHz, DMSO-d6) δ 7.46 (t, J = 9.7 Hz, 1H), 7.59–7.70 (m, 3H), 7.74 (d, J = 
8.7 Hz, 2H), 7.99 (dd, J = 6.5, 2.7 Hz, 1H), 9.24 (s, 1H), 9.36 (s, 1H). 
13C NMR (125 MHz, DMSO-d6) δ 103.64, 116.39 (q, J = 4.9 Hz), 116.46 (qd, J = 32.3, 
13.2 Hz), 117.59 (d, J = 21.5 Hz), 118.32, 119.21, 122.56 (q, J = 272.0 Hz), 124.62 (d, J 
= 8.0 Hz), 133.22, 136.04, 143.89, 152.20, 153.91 (d, J = 248.3 Hz). 
mp: 233-235 oC 
Anal Calcd for C15H9F4N3O: C, 55.73; H, 2.81; N, 13.00; Found: C, 55.95; H, 2.90; N, 
13.21. 
 
21. Synthesis of U15. 
 
A mixture of 4-aminobenzamide (3.00 g, 22.1 mmol) and 1-fluoro-4-isocyanato-2-
(trifluoromethyl)benzene (2.26 g, 11 mmol) in CH3CN (55 mL) was stirred at 80 oC 
overnight. After addition of 2 M HCl (50 mL) and H2O (250 mL), the resulting precipitate 
was filtered and crystallized from diethyl ether (10 mL) to afford 4-[3-[4-fluoro-3-
(trifluoromethyl)phenyl]ureido]benzamide (1.87 g, 50%) as a white solid. 
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1H NMR (500 MHz, DMSO-d6) δ 7.19 (brs, 1H), 7.45 (t, J = 9.7 Hz, 1H), 7.52 (d, J = 8.7 
Hz, 2H), 7.59–7.69 (m, 1H), 7.81 (brs, 1H), 7.82 (d, J = 8.7 Hz, 2H), 8.01 (dd, J = 6.5, 
2.7 Hz, 1H), 9.05 (s, 1H), 9.11 (s, 1H). 
13C NMR (125 MHz, DMSO-d6) δ 116.14 (q, J = 4.8 Hz), 116.41 (qd, J = 32.1, 13.0 Hz), 
117.40, 117.61 (d, J = 21.4 Hz), 122.61 (q, J = 271.9 Hz), 124.43 (d, J = 8.1 Hz), 127.71, 
128.51, 136.36 (d, J = 2.7 Hz), 142.14, 152.41, 153.74 (dq, J = 248.1, 2.0 Hz), 167.46. 
mp: 233-235 oC 
Anal Calcd for C15H11F4N3O2: C, 52.79; H, 3.25; N, 12.31; Found: C, 52.65; H, 3.29; N, 
12.55. 
 
22. Synthesis of U16. 
 
A mixture of 4-aminobenzoic acid (2.331 g, 17.0 mmol) in CH3CN (100 mL) and 1-fluoro-
4-isocyanato-2-(trifluoromethyl)benzene (1.69 g, 8.25 mmol) in CH3CN (3.75 mL) was 
stirred at 80 oC overnight. After addition of 2 M HCl (50 mL) and H2O (250 mL), the 
resulting precipitate was filtered and crystallized from diethyl ether (60 mL) to afford 4-[3-
[4-fluoro-3-(trifluoromethyl)phenyl]ureido]benzoic acid (1.726 g, 61%) as a white solid. 
1H NMR (500 MHz, DMSO-d6) δ 7.45 (t, J = 9.8 Hz, 1H), 7.58 (d, J = 8.7 Hz, 2H), 7.61–
7.71 (m, 1H), 7.88 (d, J = 8.7 Hz, 2H), 8.01 (dd, J = 6.5, 2.7 Hz, 1H), 9.14 (s, 1H), 9.18 
(s, 1H), 12.62 (s, 1H). 
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13C NMR (125 MHz, DMSO-d6) δ 116.22 (q, J = 5.0, 4.5 Hz), 116.42 (qd, J = 32.1, 13.1 
Hz), 117.53, 117.70, 122.60 (q, J = 272.4 Hz), 124.03, 124.49 (d, J = 8.0 Hz), 130.50, 
136.26 (d, J = 2.8 Hz), 143.64, 152.32, 153.79 (dq, J = 248.3, 2.2 Hz), 167.02. 
mp: > 380 oC 
Anal Calcd for C15H10F4N2O3: C, 52.64; H, 2.95; N, 8.19; Found: C, 52.88; H, 3.12; N, 
8.12. 
 
23. Synthesis of U17. 
 
A mixture of 3-methylisoxazol-5-amine (1.078 g, 11 mmol) in CH3CN (25 mL) and 1-
fluoro-4-isocyanato-2-(trifluoromethyl)benzene (1.128 g, 5.5 mmol) in CH3CN (2.5 mL) 
was stirred at 80 oC overnight. After addition of 2 M HCl (50 mL), the resulting precipitate 
was filtered and crystallized from diethyl ether (10 mL) to afford1-(4-fluoro-3-
(trifluoromethyl)phenyl)-3-(3-methylisoxazol-5-yl)urea (875 mg, 53%) as a white solid. 
1H NMR (500 MHz, DMSO-d6) δ 2.17 (s, 3H), 5.98 (s, 1H), 7.47 (t, J = 9.7 Hz, 1H), 7.65–
7.72 (m, 1H), 7.98 (dd, J = 6.5, 2.6 Hz, 1H), 9.20 (s, 1H), 10.31 (s, 1H). 
13C NMR (125 MHz, DMSO-d6) δ 11.34, 86.90, 116.45 (qd, J = 19.1 Hz), 116.68 (q, J = 
32.1, 13.0 Hz), 117.68 (d, J = 21.5 Hz), 122.51 (q, J = 272.7 Hz), 124.97 (d, J = 8.1 Hz), 
135.63 (d, J = 2.9 Hz), 149.92, 154.11 (dq, J = 248.8, 2.3 Hz), 160.66, 161.67. 
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mp: 180-181 oC 
Anal Calcd for C12H9F4N3O2: C, 47.53; H, 2.99; N, 13.86; Found: C, 47.60; H, 3.12; N, 
14.00. 
 
24. Synthesis of U18. 
 
A mixture of 2-aminobenzamide (1.496 g, 11 mmol) and 1-fluoro-4-isocyanato-2-
(trifluoromethyl)benzene (1.107 g, 5.4 mmol) in CH3CN (50 mL) was stirred at 80 oC 
overnight. After addition of 2 M HCl (200 mL), the resulting precipitate was filtered and 
crystallized from diethyl ether (1 mL) to afford 2-[3-[4-fluoro-3-
(trifluoromethyl)phenyl]ureido]benzamide (1.119 mg, 61%) as a white solid. 
1H NMR (500 MHz, DMSO-d6) δ 7.06 (t, J = 7.5 Hz, 1H), 7.38–7.52 (m, 2H), 7.69 (s, 1H), 
7.73–7.81 (m, 2H), 8.04 (dd, J = 6.5, 2.7 Hz, 1H), 8.25 (s, 1H), 8.30 (d, J = 8.7 Hz, 1H), 
10.08 (s, 1H), 10.84 (s, 1H). 
13C NMR (125 MHz, DMSO-d6) δ 116.08 (q, J = 4.8 Hz), 116.31 (qd, J = 32.2, 13.0 Hz), 
117.46 (d, J = 21.3 Hz), 119.82, 120.27, 121.09, 122.65 (q, J = 271.9 Hz), 124.16 (d, J = 
7.9 Hz), 128.40, 131.77, 136.90 (d, J = 2.7 Hz), 140.16, 152.37, 153.57 (dq, J = 248.0, 
1.9 Hz), 170.82. 
mp: 242-244 oC 
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Anal Calcd for C15H11F4N3O2: C, 52.79; H, 3.25; N, 12.31; Found: C, 52.55; H, 3.45; N, 
12.42. 
5.6.3. Newly transformed schistosomula (NTS) drug assay22.  
Cercariae were collected from S. mansoni-infected B. glabrata, mechanically 
transformed to schistosomula, and stored for 12 to 24 h at 37 °C and 5% CO2 in medium 
199 supplemented with 5% FCS, 100 U/ml penicillin, and 100 μg/ml streptomycin before 
use. 
For the NTS drug assay, 100 NTS per well were incubated in a 96-well plate (BD Falcon) 
with compounds diluted in supplemented medium 199 in 2-fold serial dilutions from 33.3 
to 0.26 μM, for IC50 determinations. Wells containing NTS exposed to drug-free DMSO 
at a volume equivalent to the highest drug concentration in the assay (0.3%) served as 
controls. The efficacy of the drugs was judged by scoring their overall viability, using 
phenotypic reference points such as motility, morphology, and granularity.  
 
5.6.4. Adult S. mansoni drug assay22.  
Adult S. mansoni were collected from mice by dissection at 49 to 70 days postinfection 
and were maintained in RPMI 1640 culture medium supplemented with 5% FCS, 100 
U/ml penicillin, and 100 μg/ml streptomycin at 37 °C and 5% CO2. IC50 values were 
assessed using 3-fold serial dilutions from 33.3 to 0.41 μM in duplicate, and this was 
repeated once. Compounds were diluted in supplemented RPMI medium in 24-well 
plates (BD Falcon), to which three worms of each sex were added per well. Worms 
incubated with drug-free DMSO (0.3%) served as a control. The viability of S. 




5.6.5. in vivo antischistosomal screen. 
As described by Keiser23, cercariae of S. mansoni were obtained from infected 
Biomphalaria glabrata. NMRI mice were infected subcutaneously with approximately 100 
S. mansoni cercariae. At 49 d after infection, groups of four mice were treated with 
single 100-400 mg/kg oral doses of compounds in a 7% (v/v) Tween 80% and 3% (v/v) 
ethanol vehicle (10 mL/kg).  Untreated mice (n = 8) served as controls.  At 21 d post-
treatment, animals were killed by the CO2 method and dissected.  Worms were removed 
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Schistosomiasis is caused by parasitic trematode worms of the genus 
Schistosoma in the blood vessel. The burden of disease attributable to the three major 
human schistosome species (Schistosoma mansoni, S. Haematobium, and S. japonicum) 
is estimated to be almost 200 million infected patients1. More than 90% of the roughly 200 
million cases of schistosomiasis occur in Africa2, 3 and close to 800 million are at risk. It is 
one of the most prevalent of the tropical infectious diseases4.  
In the absence of vaccines5 and with the challenges surrounding implementation 
of other preventive measures such as access to safe water and improved sanitation, the 
current and precarious mainstay for treatment and control of schistosomiasis is 
praziquantel (PZQ)6, 7. This dependence on a single drug is alarming, as there is some 
evidence that resistance to PZQ may be emerging in Africa and laboratory studies indicate 
that schistosomes exposed to repeated in vivo PZQ treatments have reduced drug 
sensitivities8, 9. Furthermore, PZQ is inactive against the juvenile schistosomula; this may 
be an important factor in the frequently observed treatment ‘failures’ in areas endemic for 
schistosomiasis. Even so, drug discovery for schistosomiasis has languished10, 11, 
although several antischistosomal lead compounds12, 13 have been identified in recent 
years.  
The aryl hydantoin Ro 13-397814 was used as a starting point in this research to 
identify several lead compounds with high antischistosomal efficacy and with minimal to 
no interaction with the host androgen receptor (AR). The overall goal of this research was 
to elucidate the SAR of aryl hydantoins and theirs derivatives. Base on a broad library of 
new analogs, a new understanding of the structural specificity of antischistosomal efficacy 
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for aryl hydantoins, diaryl ureas and urea carboxylic acids was gained, to identify potential 
novel analogs with high antischistosomal efficacy and selectivity. 
In Chapter 2, it was demonstrated that administration of 100 mg/kg oral doses of 
AH01 to mice infected with adult and juvenile Schistosoma mansoni produced 95 and 64% 
total worm burden reductions. This result confirmed its high activity against adult worms, 
and demonstrated that AH01was also effective against juvenile infections.  AH01 had no 
measureable interaction with the androgen receptor in a ligand competition assay, but it 
did block dihydrotestosterone-induced cell proliferation in an androgen-dependent human 
prostate cancer cell line. For AH01, nilutamide, and three closely related aryl hydantoin 
derivatives, there was no correlation between antischistosomal activity and androgen 
receptor interaction. 
In Chapter 3, the synthesis of several aryl hydantoin analogues is described herein. 
These compounds were prepared in an effort to probe the structure–activity relationship 
around the phenyl substituent and hydantoin core for the studies toward antischistosomal 
activity. Several of them, such as AR11, AR62, AR13, AR64, and AR43, showed 
significant antischistosomal activity and could serve as leads for further optimization. 
In Chapter 4, several efficient synthetic routes were developed to make the first 
round of urea carboxylic acid targets. These methods can be applied to the synthesis of 
structurally diverse AR37 analogs. These urea carboxylic acids could lead to an advance 
in the structure–activity relationship of this class of compounds in antischistosomal 
researches. 
In Chapter 5, the novel N,N'-diaryl ureas were designed and synthesized as new 
analogues of Ro 13-3978, some of which showed significant antischistosomal effects. The 
most promising compound identified in this work was N,N’-di(quinoxalin-2-yl)urea. A single 
200 mg/kg oral dose of AR50 administered to S. mansoni-infected mice reduced adult 
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WBR by 75.1%, while a dose of 100 mg/kg reduced WBR by 62%. This new lead 
compound can serve as a new direction for further optimization. In addition, various 
synthetic routes to diarylureas were described. 
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 Future studies 
1. Perform computational chemistry studies to elucidate the interactions between aryl 
hydantoin and human androgen receptor; 
2. Perform immunological-based experiments to dissect the disconnection between 
the low ex vivo activity and high in vivo efficacy of the aryl hydantoins. The 
experiments may elucidate the antischistosomal effects that derive from host-
independent vs. host-dependent mechanisms; 
3. Use affinity chromatography and tandem photoaffinity labeling-bioorthogonal 
conjugation to identify potential schistosome protein targets of target compounds 
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